UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities
Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒
Filed by a party other than the Registrant ☐
Check the appropriate box:
☐ Preliminary Proxy Statement
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒ Definitive Proxy Statement
☐ Definitive Additional Materials
☐ Soliciting Material Pursuant to §240.14a-12
(Name of Registrant as Specified in its Charter)
__________________________________________
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
☒ No fee required
☐ Fee paid previously with preliminary materials
☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
RADNET, INC.
1510 Cotner Ave.
Los Angeles, CA 90025
April 28, 2025
Dear Stockholder:
On behalf of the Board of Directors and management, we cordially invite you to attend the 2025 Annual Meeting of Stockholders of RadNet, Inc. (the “Annual Meeting”), to be held at our principal executive office at 1510 Cotner Avenue, Los Angeles, CA 90025, on Wednesday, June 10, 2025, at 10:00 a.m. (Pacific Time) or at any adjournment or postponement thereof. At the Annual Meeting, stockholders will vote on matters set forth in the accompanying Notice of Annual Meeting of Stockholders and Proxy Statement.
We also enclose a copy of our annual report on Form 10-K for our fiscal year ended December 31, 2024 (the “2024 Annual Report”). We encourage you to read our 2024 Annual Report, which includes information on our business, as well as our audited financial statements for the fiscal year ended December 31, 2024.
We are mailing a Notice of Internet Availability of Proxy Materials (the “Notice of Availability”) to most of our stockholders on or about April 28, 2025. The Notice of Availability contains instructions on how to access our proxy materials, including the Notice of Annual Meeting of Stockholders, Proxy Statement, 2024 Annual Report and a Proxy Card or voting instruction form and on how to cast your vote online or by phone. The Notice of Availability also contains instructions on how to request a printed copy of our proxy materials. All stockholders who do not receive the Notice of Availability will receive a printed copy of the proxy materials.
Your vote is very important. Regardless of the number of shares you own, and whether or not you plan to attend the Annual Meeting, please vote. We hope you will vote as soon as possible. You may vote by submitting your proxy via the Internet, by phone, or if you have elected to receive printed proxy materials, by completing, signing, dating and returning the Proxy Card enclosed with your printed proxy materials.
Thank you for your continued support and ownership of RadNet, Inc. We look forward to seeing you at the Annual Meeting.
Sincerely,
David Katz
Corporate Secretary
Important Notice: The Proxy Statement for the 2025 Annual Meeting of Stockholders, the Proxy Card and the 2024 Annual Report are available at www.proxyvote.com.
RADNET, INC.
1510 Cotner Ave.
Los Angeles, CA 90025
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD JUNE 10, 2025
RadNet, Inc. will hold its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on Wednesday, June 10, 2025, at 10:00 a.m. (Pacific Time) or any adjournment or postponement thereof, at our principal executive office at 1510 Cotner Avenue, Los Angeles, CA 90025.
The following items are on the agenda and are more fully described in the accompanying Proxy Statement:
| 1. | The election of six nominees as directors to hold office until the 2026 Annual Meeting of Stockholders, or until their successors are duly elected and qualified; | |
| 2. | The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; | |
| 3. | A non-binding advisory vote to approve the compensation of our Named Executive Officers; and | |
| 4. | Other business that may properly come before the Annual Meeting. |
Our Board of Directors fixed April 16, 2025 as the record date for determining stockholders entitled to notice of, and to vote at, the Annual Meeting.
We are mailing a Notice of Internet Availability of Proxy Materials to our stockholders on or about April 28, 2025, containing instructions on how to access our Proxy Statement and our Annual Report on Form 10-K for our fiscal year ended December 31, 2024 online, and how to vote online or by phone. The Notice of Internet Availability of Proxy Materials also contains instructions on how our stockholders can request a printed copy of the proxy materials.
By Order of the Board of Directors,
David Katz
Corporate Secretary
April 28, 2025
Los Angeles, California
Whether or not you expect to attend the Annual Meeting, please vote as soon as possible to ensure your representation at the Annual Meeting. You may vote online, by phone, or if you have elected to receive printed proxy materials, by completing, signing, dating and returning the Proxy Card enclosed with your printed proxy materials. Even if you give your proxy, you may still vote in person if you attend the meeting. If a broker, bank or other nominee is the record holder of your shares, then you must obtain from the record holder a proxy issued in your name in order to vote at the Annual Meeting.
RADNET, INC.
1510 Cotner Ave.
Los Angeles, CA 90025
PROXY STATEMENT
FOR ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD JUNE 10, 2025
The Board of Directors of RadNet, Inc., a Delaware corporation (“RadNet” or the “Company”), is providing these proxy materials to you in connection with the solicitation of the accompanying proxy for use at our 2025 Annual Meeting of Stockholders (the “Annual Meeting”).
The Annual Meeting will be held at our principal executive office at 1510 Cotner Avenue, Los Angeles, CA 90025, on Wednesday, June 10, 2025, at 10:00 a.m. (Pacific Time) or at any adjournment or postponement thereof, for the purposes stated in this Proxy Statement.
On or about April 28, 2025, we are mailing a Notice of Internet Availability of Proxy Materials (the “Notice of Availability”) containing instructions on how to access our Proxy Statement and our Annual Report on Form 10-K for our fiscal year ended December 31, 2024 (the “2024 Annual Report”), via the Internet and how to vote online or by phone. The Notice of Availability also contains instructions on how you can receive a printed copy of the proxy materials.
This Proxy Statement summarizes certain information to assist you in voting in an informed manner.
All stockholders are cordially invited to attend the Annual Meeting in person. Whether you expect to attend the meeting or not, please vote as soon as possible.
TABLE OF CONTENTS
Page
| i |
THE PROXY PROCESS AND THE ANNUAL MEETING
The following discussion is intended to provide general information about the proxy process and the Annual Meeting under the rules and regulations of the Securities and Exchange Commission (the “SEC”). If you have questions about this Proxy Statement or the Annual Meeting, please contact our Corporate Secretary at: RadNet, Inc., 1510 Cotner Avenue, Los Angeles, CA 90025, Attention: Corporate Secretary, Telephone: (310) 445-2800.
2025 Annual Meeting of Stockholders
| RADNET, INC. | June 10, 2025 | |
| 1510 Cotner Ave. | 10:00 a.m. Pacific Time | |
| Los Angeles, CA 90025 |
Only stockholders of record as of the close of business on April 16, 2025 (the “Record Date”) are entitled to vote at the Annual Meeting. RadNet is soliciting proxies for use at the Annual Meeting, including any postponements or adjournments.
Attending the Annual Meeting
If you are a stockholder of record as of the Record Date, you have the right to vote in person at the Annual Meeting. You will need to bring either the Notice of Availability or any Proxy Card that is sent to you to the meeting. Otherwise, you will be admitted only if we can verify your ownership of common stock on the Record Date. If you own shares held in street name, please bring with you to the meeting either the Notice of Availability or any voting instruction form, your most recent brokerage statement or a letter from your bank, broker or other record holder indicating that you beneficially owned shares of our common stock on the Record Date. We can use that information to verify your beneficial ownership of common stock and admit you to the meeting. Additionally, all persons will need to bring a valid government-issued photo ID to gain admission to the meeting.
Even if you plan to attend the Annual Meeting, we recommend that you submit your proxy or voting instructions in advance of the meeting so that your vote will be counted if you later decide not to attend the Annual Meeting.
Purpose
At the Annual Meeting, our stockholders will vote on the following items:
| 1. | The election of six nominees as directors to hold office until the 2026 Annual Meeting of Stockholders, or until their successors are duly elected and qualified; | |
| 2. | The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; | |
| 3. | A non-binding advisory vote to approve the compensation of our Named Executive Officers; and | |
| 4. | Other business that may properly come before the Annual Meeting. |
| 1 |
Proxy Materials
The following proxy materials were first sent or made available to stockholders on April 28, 2025, and include:
| · | Notice of Annual Meeting of Stockholders | |
| · | Proxy Statement for the Annual Meeting | |
| · | 2024 Annual Report |
If you requested printed versions of these proxy materials by mail, the printed proxy materials also include the Proxy Card or voting instruction form for the Annual Meeting.
Notice of Internet Availability
We are sending the Notice of Availability to our stockholders with instructions on how to access the proxy materials online or request a printed copy of the materials. Stockholders may follow the instructions in the Notice of Availability to elect to receive future proxy materials in print by mail or electronically by email. We encourage stockholders to take advantage of the availability of the proxy materials online to help reduce the environmental impact of our annual meetings and reduce RadNet’s printing and mailing costs.
Quorum for the Annual Meeting
Holders of a majority of the shares entitled to vote at the Annual Meeting must be present at the Annual Meeting in person or by proxy for the transaction of business. This is called a quorum. On the Record Date, there were 75,012,892 of our common stock issued and outstanding. Consequently, we will need to have 37,506,447 shares present in person or represented by proxy at the Annual Meeting in order to establish a quorum. Your shares will be counted for purposes of determining if there is a quorum if:
| · | You are entitled to vote and you are present in person at the Annual Meeting; or | |
| · | You have properly voted by proxy online, by phone, or by submitting a Proxy Card or voting instruction form by mail. |
Broker non-votes and abstentions are counted for purposes of determining whether a quorum is present. If a quorum is not present, we may propose to adjourn the Annual Meeting to solicit additional proxies and reconvene the Annual Meeting at a later date.
Inspector of Election
An officer of RadNet will count the votes and act as the inspector of election. The inspector of election will separately tabulate affirmative and negative votes, abstentions and broker non-votes. RadNet has also engaged Broadridge Financial Solutions, Inc. as its proxy distribution agent and tabulation service provider and they will also be calculating the votes received prior to the Annual Meeting.
Proxy Solicitation Costs
RadNet is paying the costs of the solicitation of proxies. We will also make solicitation materials available to banks, brokerage houses, fiduciaries and custodians holding shares of our common stock in their names but that are beneficially owned by others for forwarding to the beneficial owners. We may reimburse persons representing beneficial owners of common stock for their costs of forwarding solicitation materials to the beneficial owners. Solicitations will be made primarily through the Notice of Availability, but may be supplemented by telephone, facsimile, Internet or personal solicitation by our directors, executive officers and employees. No additional compensation will be paid to these individuals for these services.
| 2 |
Voting
Each share of RadNet’s common stock has one vote on each matter. Only “shareholders of record” as of the close of business on the Record Date are entitled to vote at the Annual Meeting. As of the Record Date, there were 75,012,892 shares of RadNet’s common stock issued and outstanding, held by 3,588 shareholders of record. In addition to shareholders of record of RadNet’s common stock, “beneficial owners of shares held in street name” as of the Record Date can vote using the methods described below.
If your shares are registered directly in your name with RadNet’s transfer agent, Equiniti Trust Company, LLC, you are the shareholder of record with respect to those shares.
If your shares are held in an account at a bank, broker, or other organization, then you are the “beneficial owner of shares held in street name.” As a beneficial owner, you have the right to instruct the person or organization holding your shares how to vote your shares. Most individual shareholders are beneficial owners of shares held in street name.
With respect to Proposal No. 1 (the election of directors), stockholders may vote “FOR” all nominees, “WITHHOLD” authority for all nominees, or vote “FOR” all except for those individual nominees for director for which the stockholder indicates it is withholding authority. With respect to each other proposal, stockholders may vote “FOR” the proposal, “AGAINST” the proposal, or abstain from voting.
Voting Procedures
There are four ways to vote:
| · | Online. If you are a shareholder of record, you may vote by proxy by visiting www.proxyvote.com and entering the control number found in the Notice of Availability. If you are the beneficial owner of shares in street name, the availability of online voting will depend on the voting procedures of the organization that holds your shares. Stockholders who submit a proxy online need not return a Proxy Card or the form forwarded by your broker, bank, trust or other holder of record. | |
| · | Phone. If you are a shareholder of record and request printed copies of the proxy materials by mail, you will receive a Proxy Card or voting instruction form and you may vote by proxy by calling the toll-free number found on the card or form. If you are a beneficial owner of shares in street name, the availability of phone voting will depend on the voting procedures of the organization that holds your shares. Stockholders who submit a proxy by phone need not return a Proxy Card or the form forwarded by your broker, bank, trust or other holder of record. | |
| · | Mail. If you are a shareholder of record and request printed copies of the proxy materials by mail, you will receive a Proxy Card or voting instruction form and you may vote by proxy by completing, dating and signing the Proxy Card or voting instruction form and returning it in the envelope provided. | |
| · | In Person. If you are a shareholder of record, you may vote in person at the Annual Meeting by requesting a ballot. If you beneficially hold shares in street name and wish to vote in person at the Annual Meeting, you must also obtain a “legal proxy” from the organization that holds your shares and bring it to the Annual Meeting. A legal proxy is a written document that authorizes you to vote your shares held in street name at the Annual Meeting. Please contact the organization that holds your shares for instructions regarding obtaining a legal proxy. In order for your vote to be counted, you must hand both the copy of the legal proxy and your completed ballot to a Company representative to be provided to the inspector of election. |
| 3 |
All shares represented by valid proxies received prior to the taking of the vote at the Annual Meeting will be voted and, where a stockholder specifies by means of the proxy a choice with respect to any matter to be acted upon, the shares will be voted in accordance with the stockholder’s instructions.
Changing your Vote
You may revoke your proxy and change your vote at any time before the taking of the vote at the Annual Meeting, as follows:
| · | Online. You may change your vote using the online voting method described above, in which case only your latest online proxy submitted prior to the Annual Meeting will be counted. | |
| · | Phone. You may change your vote using the phone voting method described above, in which case only your latest telephone proxy submitted prior to the Annual Meeting will be counted. | |
| · | Mail. You may revoke your proxy and change your vote by signing and returning a new Proxy Card or voting instruction form dated as of a later date, in which case only your latest Proxy Card or voting instruction form received prior to the Annual Meeting will be counted. | |
| · | In Person. You may revoke your proxy and change your vote by attending the Annual Meeting and voting in person. However, your attendance at the Annual Meeting will not automatically revoke your proxy unless you properly vote at the Annual Meeting or specifically request that your prior proxy be revoked by delivering a written notice of revocation prior to the Annual Meeting to RadNet’s Corporate Secretary. |
If you have already voted and do not wish to change your vote, you do not need to take any further action and your shares will be voted as originally directed by you.
Vote Required to Approve a Proposal
RadNet’s bylaws provide that, in an uncontested election of directors—one where the number of candidates for election does not exceed the number of directors to be elected—the affirmative vote of a majority of the shares present or represented by proxy and entitled to vote at the Annual Meeting is required to elect a director.
Accordingly, approval of Proposals Nos. 1, 2 and 3 requires, in each case, the affirmative vote of a majority of the shares present or represented by proxy and entitled to vote on the subject matter at the Annual Meeting.
Uninstructed Shares and Broker Non-Votes
Shareholder of Record
If you are a shareholder of record and submit a valid proxy or voting instruction form but do not indicate your specific voting instructions on one or more of the proposals, your shares will be voted as recommended by our Board of Directors (“Board of Directors” or “Board”) on those proposals and as the proxyholders may determine in their discretion with respect to any other matters properly presented for a vote at the Annual Meeting.
| 4 |
Beneficial Owner in Street Name
Banks, brokers and nominees will vote shares in accordance with instructions from the beneficial owners of shares held in street name. If you are a beneficial owner of shares held in street name, and if the bank, broker or other nominee that holds your shares does not receive specific voting instructions, it has discretionary authority to vote your shares on “routine” matters, but not on “non-routine” matters.
The following proposal is considered a routine matter:
| · | Proposal 2: The ratification of the appointment of Ernst & Young LLP as RadNet’s independent registered public accounting firm for the fiscal year ending December 31, 2025. |
The following proposals are considered non-routine matters:
| · | Proposal 1: Election of directors; and | |
| · | Proposal 3: A non-binding advisory vote to approve the compensation paid to our Named Executive Officers. |
Broker Non-Votes
When the organization that holds your shares does not receive instructions from you on how to vote your shares on a “non-routine” proposal, that organization will inform the inspector of election that it does not have the authority to vote on the matter with respect to your shares. This is generally referred to as a “broker non-vote.” Broker non-votes are counted for the purposes of determining whether a quorum is present. However, broker non-votes will not be counted as having voting power to vote on Proposal No. 1 and Proposal No. 3 and will have no effect on non-routine matters of Proposal No. 1 and Proposal No. 3. Thus, you must instruct your bank, broker or nominee on how to vote your shares for the non-routine matters of Proposal No. 1 and Proposal No. 3 in order for your vote to count for those proposals.
Abstentions
Abstentions are counted for purposes of determining whether a quorum is present. Abstentions will have the effect of a vote of “AGAINST” for a director in Proposal No. 1, and “AGAINST” Proposal Nos. 2 and 3.
Confidentiality of Votes
Proxy instructions, ballots, and voting tabulations that identify individual stockholders are handled in a manner that protects your voting privacy. Your vote will not be disclosed either within RadNet or to third parties, except: (1) as necessary to meet applicable legal requirements and (2) to allow for the tabulation of votes and certification of the vote. Occasionally, stockholders include additional comments on their Proxy Card or with their voting instruction form, which are then forwarded to our management.
Tabulation and Reporting of Voting Results
Final voting results will be tallied by the inspector of election after the taking of the vote at the Annual Meeting. RadNet will publish the final voting results in a Current Report on Form 8-K filed with the SEC within four business days of the Annual Meeting.
Director and Officer Interest in Matters to be acted Upon at the Annual Meeting
Members of the Board of Directors and executive officers do not have an interest in Proposal No. 2. Our executive officers have an interest in Proposal No. 3 as the proposal relates to the compensation of our Named Executive Officers.
| 5 |
ENVIRONMENTAL
We seek to manage and evolve our operations in ways to minimize our impact on the environment as part of our commitment to improving health in the communities we serve.
Healthcare imaging is dependent on technologically advanced equipment, that uses significant energy in its operation. While we do not design or manufacture the equipment that we install in our facilities, we take a number of actions aimed at reducing our overall energy consumption:
| · | We seek to maximize the utilization of equipment at our facilities. Efficient patient scheduling and high utilization of our machines reduces the energy consumed during idle periods where equipment is not contributing to patient care. We also try to power down imaging equipment that can safely and efficiently be powered down when not in use during off-hours. | |
| · | We monitor the air conditioning systems at our imaging facilities. We generally set thermostats in common areas to eco-friendly levels based on the particular geographical environment. We use window shades, or other coverings, to reduce our cooling requirements. We replace older HVAC systems with newer, more energy efficient models when warranted, and conduct preventative maintenance on the HVAC systems to assure operating efficiency. | |
| · | Lighting systems in many of our imaging centers are equipped with motion sensors, timers and dimmers, to reduce unnecessary use. We are also in the process of converting older conventional lighting systems to newer systems using lower wattage LED lights. | |
| · | Our imaging centers in California are subject to California Title 24 Building Energy Efficiency Standards, a set of standards for energy consumption designed to ensure new and existing buildings achieve energy efficiency. |
| 6 |
SOCIAL RESPONSIBILITY
Our social responsibility begins with our patients and extends to our employees and consultants and to the communities in which we operate.
We operate imaging centers to facilitate the diagnosis and treatment of diseases and disorders. Our services may reduce unnecessary invasive medical procedures, improve patient care and reduce the cost and amount of care for patients in the communities that we serve. At our imaging centers, we focus on providing standardized high quality imaging services, regardless of location, to ensure patients, physicians and payors consistency in service and quality. To ensure the high quality of our services, we monitor patient satisfaction, timeliness of services to patients and reports to physicians.
At our centers, we seek to provide state of the art facilities, with multiple imaging modalities, access to newer equipment and a highly-trained staff. Although currently small in scope, we are investing in Artificial Intelligence (“AI”) technologies which we believe have the potential to significantly change the medical imaging industry. We are developing applications to aid radiologists in scan interpretation by quickly allowing comparison to large imaging databases to enable pinpoint diagnosis in shorter time frames. In addition, AI methods can also keep track of individuals needing procedures on a regular basis (i.e. mammograms, follow ups, etc.) and alert our staff to contact the patient and schedule appointments.
The strength of our workforce is critical to the success of our mission to provide comprehensive radiology solutions and change the future of healthcare. We are focused on attracting, retaining, and developing the talent we need to deliver on our commitment to our patients and partners. At December 31, 2024, there were a total of 8,558 full-time, 1,407 part-time, 1,002 per-diem, and 20 temporary employees. These numbers include 198 full-time and 64 part-time physicians and 2,338 full-time, 772 part-time, 639 per-diem and 7 temporary technologists.
We are keenly aware of the value of a diverse workforce and are proud of our track record. Approximately 81% of our workforce at December 31, 2024 was female and 56% were from under-represented groups.
Our culture of diversity and inclusion enables us to exceed the expectations of our patients and meet our growth strategy. Our success in inclusion and diversity objectives are the result of strong leadership, transparency and accountability. While our workforce demographics clearly indicate our success in achieving a highly diverse team, in order to foster even stronger understanding of diversity, equity and inclusion, we have developed an internal education program to ensure all of our team are aware of our closely held values. Our initiatives include corporate support and sponsorship of community outreach/enrichment programs and high school, vocational school, and collegiate outreach.
We invest in our employees to ensure their confidence and competence in their roles, as well as to provide a path for professional career development. We provide a range of internal education and development programs and opportunities to support the advancement of our employees. RadNet offers a Leadership Development and Operations Rotation Program, Management Training, Technical Scholarship, and various modality education and training support programs. We offer both formal and informal programs to identify, foster and retain top talent. We maintain a Tuition Reimbursement Program which encourages professional development for our incumbent team, and we also sponsor undergraduate and graduate education and advanced technical training for various incumbent team members.
We provide compensation that is competitive and consistent with employee positions, skill levels, and experience. We align our executives’ and eligible non-executive employees’ long-term equity compensation with our stockholders’ interests. Our employees are eligible for benefits that are industry-leading, including preferred provider organization and high deductible health plan medical plans with a company sponsored health savings account, wellness plans that include financial incentives, free radiology procedures for team and family, paid life insurance and accidental death and dismemberment insurance , dental insurance, vision insurance, Employee Assistance Plan with enhanced mental health benefits, group paid long and short term disability plans, 401(k), tuition reimbursement, access to instant earned wages through DailyPay, paid and unpaid leave, flexible working schedule, and a variety of voluntary benefits including Colonial, Supplemental Life, Dependent Life and Commuter benefits and free flu vaccinations.
| 7 |
CORPORATE GOVERNANCE
Role of the Board of Directors
Our business is managed under the direction of our Board of Directors. Our Board of Directors provides oversight, strategic direction, and counsel to our management. In addition, our Board of Directors elects our officers, delegates responsibilities for the conduct of our operations to those officers, and evaluates their performance.
Our Board of Directors held six meetings during 2024 and took action by written consent on five occasions. Each of our directors serving in 2024 attended 100% of the total number of meetings of the Board of Directors and applicable committees that each director was eligible to attend.
Board Leadership Structure
Our Chairman of the Board of Directors, Dr. Berger, also serves as our Chief Executive Officer. Our Board of Directors has determined that this leadership structure is appropriate and effective for RadNet at this time. This structure effectively utilizes Dr. Berger’s knowledge of RadNet and the industry in which we operate, while fostering greater communication and producing a greater degree of transparency between management and our directors. Dr. Berger co-founded RadNet in 1980 and has served as Chairman of the Board and Chief Executive Officer for nearly 40 years.
David L. Swartz currently serves as Lead Independent Director of the Board of Directors. In this capacity, Mr. Swartz serves as Chairman of meetings of the Board of Directors in the absence of the Chairman of the Board, calls, sets the agenda, and chairs the executive sessions of the independent directors, works collaboratively with the Chairman of the Compensation Committee to oversee the evaluation of our Chief Executive Officer and serves as the liaison between the independent directors and the Chairman of the Board.
Director Independence
Our Board of Directors annually determines the independence of our directors in accordance with the independence requirements under the NASDAQ Stock Market LLC (“NASDAQ”) and the SEC rules which require at least a majority of the directors to be independent. As a result of this review, our Board of Directors has determined that Lawrence L. Levitt, Laura P. Jacobs, Gregory E. Spurlock and David L. Swartz each qualifies as an independent director in accordance with the NASDAQ and the SEC rules.
Each of Howard G. Berger, M.D. and A. Gregory Sorensen, M.D. is an employee of RadNet and therefore does not qualify as an independent director under the NASDAQ and the SEC rules.
Majority Voting for Election of Directors
Under our bylaws, directors must be elected by a majority of the shares present and entitled to vote in elections for which the number of nominees for election does not exceed the number of directors to be elected. A plurality vote standard applies to contested elections where the number of nominees exceeds the number of directors to be elected.
We have adopted a Director Resignation Policy that provides that any incumbent director who does not receive a majority of the votes cast in an uncontested election is required to tender their resignation for consideration by the Nominating and Governance Committee. The Nominating and Governance Committee will make a recommendation to the Board on whether to accept or reject the resignation, or take other action. The director who tenders their resignation will not participate in the Nominating and Governance Committee or Board’s decision. In making its determination the Board will consider (a) the underlying reason for the vote result, if known, (b) the director’s contributions to the Company during his or her tenure, and (c) the director’s qualifications. The Board may accept the resignation, refuse the resignation, or refuse the resignation subject to such conditions designed to cure the underlying cause as the Board may impose. Promptly following the decision regarding the tendered resignation, the Company will file with the SEC a current report on Form 8-K disclosing the decision with respect to the resignation, describing the deliberative process and, if applicable, the specific reasons for rejecting the tendered resignation.
| 8 |
Diversity
Our Board believes that diversity brings forward different perspectives and improves decision-making and governance. While we don’t have a formal diversity policy, our Nominating and Governance Committee considers several criteria when evaluating candidates for director, including, among others, the individual and aggregate characteristics, professional backgrounds, diversity, independence, judgement and areas of expertise with the goal of a well-balanced and effective Board, and other characteristics that contribute to diverse viewpoints when identifying nominees for our Board of Directors.
Director Continuing Education
We support director education initiatives throughout a director’s tenure on the Board. We host “teach-ins” where members of our management meet with the Board to review industry trends and the Company’s operations in a number of subject areas. Recent teach in sessions have covered topics such as:
| · | Cyber Security | |
| · | Human Capital, including Talent Acquisition, Employee Engagement, Recruiting and Retention | |
| · | Revenue Cycle – Billing & Collections, Credit Balances | |
| · | Regulatory Compliance |
We encourage all directors to attend continuing education programs and to share information and observations from those programs with other directors. We reimburse directors for reasonable expenses incurred in attending continuing education programs.
Committees of the Board of Directors
Our Board of Directors has three standing committees: the Audit Committee, the Compensation Committee and the Nominating and Governance Committee. The committees are comprised entirely of independent directors. Each committee operates under a written charter adopted by the Board of Directors, which is available at www.radnet.com under Investor Relations – Corporate Governance.
The current composition of the committees is as set forth below:
|
Director |
Audit Committee |
Compensation Committee |
Nominating and Governance Committee |
| Lawrence L. Levitt | • | C | • |
| Laura P. Jacobs | • | • | C |
| Gregory E. Spurlock | • | • | |
| David L. Swartz | C | • | • |
_____________
“C” denotes chair of committee
| 9 |
Audit Committee
The Audit Committee’s responsibilities include, among other things:
| · | overseeing the engagement, qualifications, independence, compensation, retention and performance of the Company’s independent auditors and the conduct of the annual independent audit of the Company’s financial statements; | |
| · | overseeing the integrity of the Company’s financial statements and other financial information provided by the Company to its stockholders, any governmental or regulatory body and others; | |
| · | monitoring the auditing, accounting and financial reporting processes and systems of internal control that are conducted by the Company’s independent auditors, internal audit function and the Company’s financial and senior management; and | |
| · | preparing the report of the Audit Committee required by the rules of the SEC to be included in the Company’s annual proxy statement. |
The Board of Directors has determined that each of Mr. Swartz and Mr. Levitt qualifies as an “audit committee financial expert” as defined under the applicable SEC rules and that each member of the Audit Committee meets the additional criteria for independence of Audit Committee members under Rule 10A-3(b)(1) of the Exchange Act.
The Audit Committee held four meetings and did not take any actions by written consent in 2024.
Compensation Committee
The Compensation Committee’s responsibilities include, among other things:
| · | assisting the Board in developing and reviewing compensation programs and strategy applicable to the Company’s directors and senior executives, and overseeing the Company’s overall compensation philosophy; | |
| · | making recommendations to the Board with respect to incentive compensation plans and equity-based plans, and interpreting and administering such plans; | |
| · | reviewing and discussing with the Company’s management the tables and narrative discussion and analysis regarding executive officer and director compensation policies and practices to be included in the Company’s public filings, including its annual proxy statement and annual report on Form 10-K; and | |
| · | preparing the Compensation Committee Report to be included in the Company’s proxy statement and annual report on Form 10-K, in accordance with the rules and regulations of the SEC. |
The Compensation Committee held four meetings and took action by written consent on one occasion in 2024.
| 10 |
Nominating and Governance Committee
The Nominating and Governance Committee’s responsibilities include, among other things:
| · | independently overseeing the director nomination process and procedures; | |
| · | identifying, evaluating and recommending to the Board for election and/or appointment qualified candidates for membership on the Board or its committees; | |
| · | developing, reviewing, and recommending to the Board corporate governance policies, procedures and guidelines and otherwise shaping the Company’s corporate governance; | |
| · | investigating and approving related party transactions, establishing and maintaining director conflicts of interest policies, and making recommendations to the Board with respect to the “independence” of directors; and | |
| · | monitoring and overseeing evaluation of the Board and its committees, management’s performance, and succession planning for executive management. |
The Nominating and Governance Committee did not hold any meeting but took action by written consent on one occasion in 2024.
Retention of Outside Advisors
The Board and all of its committees have authority to retain outside advisors and consultants that they consider necessary or appropriate in carrying out their respective responsibilities. Our independent registered public accounting firm is retained by, and reports directly to, the Audit Committee. Similarly, the Compensation Committee retains a compensation consultant to assist in evaluating executive compensation which reports directly to that committee.
Board Role in Risk Oversight
Our Board of Directors performs an oversight role in managing RadNet’s risk. In reviewing our strategy, business plan, budgets and historical and anticipated future major transactions, the Board of Directors considers, among other factors, the risks RadNet faces and how such risks can be appropriately managed. While our Board of Directors oversees risk management strategy, our management is responsible for implementing and supervising day to day risk management processes. Our senior management regularly reports to the Board of Directors on areas of material risk, including operational, financial, legal and strategic risks, which enables the Board of Directors to understand management’s views and strategies regarding risk identification, risk management and risk mitigation.
In addition to the oversight role assumed by the full Board of Directors, various committees of the Board of Directors also have responsibility for risk management. The Director of Internal Audit reports directly to our Audit Committee on areas of material financial risk, including internal controls, and the Audit Committee reports to the full Board of Directors on risks identified by the Director of Internal Audit that the Audit Committee believes to be material. In addition, the Compensation Committee oversees the risks associated with our compensation policies and practices to ensure that the compensation programs and incentives do not encourage short term risk taking at the expense of long term results or create risks that may have a material adverse effect on RadNet.
| 11 |
Corporate Governance Guidelines
The Board has adopted Corporate Governance Guidelines to formalize certain policies and provide guidance in the exercise of its governance responsibilities. The Corporate Governance Guidelines cover areas such as:
| · | The Role of the Board of Directors | |
| · | Board Size and Composition | |
| · | Terms for Director Service | |
| · | Meetings and procedures | |
| · | Board Committees | |
| · | Communications to and From Directors | |
| · | Director Compensation | |
| · | Performance Evaluation | |
| · | Management Review | |
| · | Succession Planning |
The Nominating and Governance Committee is responsible for reviewing and making recommendations for amendment of the Corporate Governance Guidelines from time to time. The Corporate Governance Guidelines are available at on our website at: www.radnet.com/investor-relations under Corporate Governance.
Code of Financial Ethics
We have adopted a written Code of Financial Ethics that is applicable to our directors, officers and employees and is designed to deter wrongdoing and to promote:
| · | honest and ethical conduct; | |
| · | full, fair, accurate, timely and understandable disclosure in reports and documents that we file with the SEC and in other public communications; | |
| · | compliance with applicable laws, rules and regulations, including insider trading compliance; and | |
| · | accountability for adherence to the code and prompt internal reporting of violations of the code, including illegal or unethical behavior regarding accounting or auditing practices. |
| 12 |
You may obtain a copy of our Code of Financial Ethics on our website at www.radnet.com/investor-relations under Corporate Governance. The Board of Directors has designated the Audit Committee with the responsibility for reviewing the Code of Financial Ethics and making any appropriate updates or amendments. We intend to disclose any changes in this code or waivers from this code that apply to our principal executive officer, principal financial officer, or principal accounting officer by posting such information to our website or by filing with the SEC a Current Report on Form 8-K, in each case if such disclosure is required by SEC or Nasdaq rules.
Review and Approval of Related Party Transactions
Under its current charter, our Nominating and Governance Committee reviews and determines whether or not to approve any transaction between RadNet and its directors, director nominees, executive officers and greater than 5% beneficial owners and each of their respective immediate family members where the amount involved in the transaction exceeds or is expected to exceed $120,000 in a single year and the related party has or will have a direct or indirect interest in the transaction.
Howard G. Berger, M.D., is our President and Chief Executive Officer, a Chairman of our Board of Directors, and also owns, indirectly, 99% of the equity interests in Beverly Radiology Medical Group III (“BRMG”). BRMG is a professional general partnership responsible for the professional medical services at nearly all of our facilities located in California and Arizona under a management agreement with us, and employs physicians or contracts with various other independent physicians and physician groups to provide the professional medical services at most of our California and Arizona facilities. We generally obtain professional medical services from BRMG in California and Arizona, rather than provide such services directly or through subsidiaries. We have a management agreement with BRMG, which automatically renewed for a 10-year period on January 1, 2024. Under our management agreement, BRMG pays us, as compensation for the use of our facilities and equipment and for our services, a percentage of the gross amounts collected for the professional services it renders. The percentage, which was 81% at December 31, 2024, is adjusted, if necessary, to ensure that the parties receive fair value for the services they render. In operation and historically, the annual revenue of BRMG from all sources closely approximates its expenses, including Dr. Berger’s compensation, fees payable to us and amounts payable to third parties. In 2024, Dr. Berger received $1.0 million of his salary and his entire cash bonus payment of $4.0 million from BRMG.
On January 1, 2022, we entered into a lease agreement with HFB Heirs Trust II, the holder of approximately 7.2% of our outstanding common stock, with respect to a residential unit located in New York, New York. Under the lease agreement we have agreed to pay rent of $15,000 per month to HFB Heirs Trust II. The initial term of the lease agreement was for 24 months, subject to automatic renewal for successive three-month periods on the same terms and conditions. Our Audit Committee reviewed and approved the terms of the lease agreement.
Board Evaluations
Our Board of Directors engages in an annual self-assessment process, which is designed to elicit feedback on areas where the Board is performing well, and areas where it could improve. Under the terms of their respective charters, each of our Committees engages in an annual review of their performance. The Nominating and Governance Committee has responsibility for overseeing the self-evaluation process for the Board of Directors and its committees.
Every other year, we engage Nasdaq Boardvantage to assist with our self-assessment process. In connection with that process, each director completes a separate detailed assessment to evaluate the Board and each committee on which they serve. The assessment covers areas such as Board and committee size, strategy and oversight, communication, meeting procedures and content, and effectiveness. The Chief Legal Officer coordinates delivery of the responses to the Lead Independent Director and the chair of each committee. Each committee chair meets separately with each of its members to discuss the results of that committee’s assessment.
| 13 |
Succession Planning
Our Board of Directors, together with the Nominating and Governance Committee, shares responsibility for succession planning for our CEO and executive management team. As part of its role, our Nominating and Governance Committee reviews management development and succession planning to ensure that there are adequate identified and qualified candidates who can assume top management positions without undue interruption. This process is designed to prepare the Company for both expected successions, such as those arising from anticipated retirements, as well as those occurring when executives leave unexpectedly, or due to death, disability, or other unforeseen events. We maintain emergency succession plans for the CEO and other executive committee members.
In developing its succession plans, and assessing possible CEO and other senior leadership candidates, our Nominating and Governance Committee identifies the skills, experiences, and attributes they believe are required to be an effective leader in light of the Company’s business strategies, opportunities, and challenges. Members of our Nominating and Governance Committee have direct access to members of our senior management team. Members of senior management are invited regularly to make presentations at Board and committee meetings and meet with directors in informal settings to allow the directors to form a more complete understanding of the executives’ skills and character. Succession reviews and planning for executive roles includes an assessment of internal candidates as well as external talent.
Board Attendance at Annual Meetings of Stockholders
None of our directors or stockholders attended the 2024 Annual Meeting of Stockholders.
Shareholder Engagement
Our Board values an open dialogue with shareholders, believing that regular communication is a critical part of the Company’s long-term success. Through these activities, the Board discusses the Company’s corporate governance, executive compensation programs, and other topics of interest to shareholders. We also closely monitor policy statements and areas of focus for shareholders. These engagement efforts allow the Board to better understand the Company’s shareholders’ priorities and perspectives and provide the Board with useful input concerning the Company’s compensation, corporate governance, and other practices. In addition, our Chief Financial Officer regularly engages with existing and prospective stockholders, as well as the Company’s lenders.
We have undertaken a number of actions based on the recommendations of our stockholders to strengthen our governance practices and disclosure. We have voluntarily implemented a majority voting standard in uncontested director elections and added the Director Skills matrix to this Proxy Statement to describe each director’s qualifications.
Communication with our Board of Directors
Stockholders and other interested parties may communicate with our Board of Directors through the Corporate Secretary by writing to the following address: Board of Directors, c/o Corporate Secretary, RadNet, Inc., 1510 Cotner Avenue, Los Angeles, CA 90025. The envelope containing such communication should contain a clear notation that the letter is “Stockholder-Board Communication” or “Stockholder-Director Communication” or a similar statement to indicate it is intended for the Board of Directors. All such communications must clearly indicate the author as a stockholder and state whether the intended recipients are all members of the Board of Directors or certain specified directors.
| 14 |
DIRECTORS
Nomination Process
Our Nominating and Governance Committee recommends nominees to the Board of Directors for election after carefully considering all candidates, taking into account the qualifications set forth in the Nominating and Governance Committee Charter and all factors the Nominating and Governance Committee considers appropriate, which may include career specialization, relevant technical, leadership or governance skills, or financial acumen, industry knowledge, other board service, and diversity of viewpoint (including diversity of race, ethnicity, gender, age, education, cultural background, and professional experience).
Our Nominating and Governance Committee Charter contains our policy with regard to the consideration of diversity in the identification of director nominees. As part of its evaluation of Board composition, the Nominating and Governance Committee considers the diversity of candidates to ensure that our Board of Directors is comprised of individuals with a broad range of experiences, skills and backgrounds who can contribute to the Board’s overall effectiveness in carrying out its responsibilities and can represent diverse viewpoints on our Board of Directors. The Nominating and Governance Committee assesses the effectiveness of these efforts when evaluating the composition of the Board of Directors as part of the annual nomination process.
The Nominating and Governance Committee considers stockholder nominees made in accordance with our bylaws, and evaluates candidates recommended by stockholders in the same manner as all other candidates brought to the attention of the Nominating and Governance Committee. Stockholder recommendations may be submitted to the Nominating and Governance Committee in care of the Corporate Secretary at the address set forth under “Communication with our Board of Directors.”
Nominees for Election
The names of the director nominees, their ages as of March 31, 2025, and other information about them are set forth below. All nominees currently serve on the Board of Directors.
|
Name of Director Nominee |
Age |
Position |
Our Director Since |
| Howard G. Berger, M.D. | 80 | Chairman of the Board, Chief Executive Officer and President | 1992 |
| A. Gregory Sorensen, M.D. | 63 | Director, Chief Science Officer | 2023 |
| Laura P. Jacobs | 68 | Director | 2020 |
| Lawrence L. Levitt | 82 | Director | 2005 |
| Gregory E. Spurlock | 63 | Director | 2021 |
| David L. Swartz | 81 | Director | 2004 |
The following biographies describe the skills, qualities, attributes, and experience of the nominees that led the Board of Directors and the Nominating and Governance Committee to determine that it is appropriate to nominate these directors for election to the Board of Directors.
Howard G. Berger, M.D. has served as President and Chief Executive Officer of RadNet and its predecessor entities since 1987. Dr. Berger received his M.D. at the University of Illinois Medical School, is Board Certified in Nuclear Medicine and trained in an Internal Medicine residency, as well as in a master’s program in medical physics in the University of California system. Dr. Berger is also the president or co-president of the entities that own Beverly Radiology Medical Group III (“BRMG”). Dr. Berger brings senior business leadership skills to our Board of Directors and deep industry knowledge derived from his nearly 40 years of experience in the development and management of RadNet.
| 15 |
A. Gregory Sorensen, M.D. was appointed as our Chief Science Officer and as a director in August 2023. Dr. Sorensen has served as the Chief Executive Officer of our DeepHealth, Inc. (“DeepHealth”) subsidiary of the Company that is focused on using artificial intelligence and deep learning methods to advance medical care with a special emphasis on breast cancer imaging. The Company acquired DeepHealth in June 2020. Dr. Sorensen served as the President and Chief Executive Officer of Siemens Healthcare North America from 2011 to 2015. Prior to that, he served as a Professor at Harvard Medical School and as a neuroradiologist at Massachusetts General Hospital, where he worked from 1990 to 2011. Dr. Sorensen currently serves as: the Executive Chairman of the board of directors of IMRIS, Deerfield Imaging, Inc., which is focused on the integration of imaging technologies in a neurosurgical setting; a member of the board of directors for RealmIDX, Inc., an integrated diagnostics company wholly owned by KonicaMinolta; and a member of the Supervisory Board for Fresenius Medical Care AG & Co KGaA, a provider of products and services for people with chronic kidney failure. Dr. Sorensen served as a Supervisory Board Member at Siemens Healthineers from 2018 to 2023. Dr. Sorensen holds a B.S. in biology from the California Institute of Technology, an M.S. in computer science from Brigham Young University, and an M.D. degree from Harvard Medical School. Dr. Sorensen brings broad-based expertise on the development and potential impact of new technologies, including artificial intelligence and machine learning, on imaging services and healthcare.
Laura P. Jacobs has been a member of our Audit Committee, our Nominating and Governance Committee and our Compensation Committee since 2020. Ms. Jacobs retired from her position as managing principal of GE Healthcare Partners in 2020, where she worked since 1990. Ms. Jacobs led the firm’s US healthcare management consulting business from 2015 to 2019 and was a founding principal and executive leader of its predecessor consulting firm, The Camden Group. She is currently a part-time Senior Advisor for Kaufman Hall, a consulting division of Vizient. She is a national expert on healthcare trends and their impact on providers and has been involved in healthcare management for the past 40 years, including the 30 years with GE Healthcare Partners/The Camden Group, advising healthcare providers regarding strategies, operations and financial performance improvement initiatives. Ms. Jacobs has advised physician organizations, complex health systems and other healthcare entities on strategies for growth, technology adoption and financial performance improvement. Ms. Jacobs has led strategic, financial and operational redesign of health systems, including transforming the framework for decision-making and care delivery. Ms. Jacobs has led the organizational and compensation redesign for provider organizations to achieve greater integration and aligned incentives. She is a published author and speaker regarding current trends in healthcare, payer strategies, risk-based payment models, consumer expectations, clinical integration, governance and performance optimization. She currently serves as Chair of Front Porch, a nonprofit organization that owns and manages retirement and affordable housing communities. Ms. Jacobs brings to our Board a wealth of experience in operating, managing and growing healthcare companies.
Lawrence L. Levitt has been a member of our Audit Committee since March 2005 and a member of our Nominating and Governance Committee since 2011. Mr. Levitt has served as Chair of our Compensation Committee since 2007. Mr. Levitt is a certified public accountant and received his MBA in Accounting from the University of California Los Angeles. Since 1987, Mr. Levitt has been the President, Chief Financial Officer of Canyon Management Company, a company which manages a privately held investment fund. Mr. Levitt brings to our Board of Directors extensive financial accounting experience and is an audit committee financial expert under the SEC rules.
Gregory E. Spurlock has been a member of our Compensation Committee and our Nominating and Governance Committee since 2021. Mr. Spurlock is currently a Senior Advisor to Global Medical Response, a KKR company with over 38,000 employees that provides emergency response to the ill and injured. From to August 2019 to August 2024, Mr. Spurlock served as a Senior Advisor to LLR Partners, a Philadelphia-based private equity fund with a focus on health care. He retired in 2019 as President of Alliance Healthcare Services, where he directed operations for their professional, technical, and global hospital-based services, encompassing 40 centers across 19 states. Mr. Spurlock helped lead U.S. Radiosurgery, LLC, through its acquisition by Alliance HealthCare Services in 2011. As a member of the senior executive team, he led Alliance Healthcare’s transition from publicly traded to international privately-owned in 2017. Previous leadership includes work as the Director of the Tennessee Orthopaedic Alliance in Nashville and Executive Director of the Kerlan-Jobe Orthopedic Clinic in Los Angeles. Mr. Spurlock has served on a number of boards, including the CyberKnife Coalition, the Corporate Advisory Council of the American Society for Radiation Oncology, and the Board of Directors of the American Association of Orthopaedic Executives. He holds a Bachelor of Science degree from Virginia Tech. Mr. Spurlock brings extensive operational, management and industry experience to our Board.
| 16 |
David L. Swartz has been Chair of our Audit Committee since 2004, has been a member of our Nominating and Governance Committee since 2007, a member of our Compensation Committee since 2007 and was appointed as Lead Independent Director in 2011. Mr. Swartz is a certified public accountant (retired) with experience providing accounting and advisory services to clients. Since 2010, Mr. Swartz has owned and continues to operate his own consulting services firm. Mr. Swartz served as a member of the Board of Directors of the California State Board of Accountancy until November 2012 and previously served as its president. From 2008 to 2010, Mr. Swartz served as a partner at J.H. Cohn LLP. Between 1990 and 2008, Mr. Swartz served as the managing partner of Good, Swartz, Brown & Berns LLP which was acquired by J.H. Cohn LLP in 2008. Prior to 1988, Mr. Swartz served as managing partner and was on the national Board of Directors of a 50 office international accounting firm. Mr. Swartz brings to our Board of Directors extensive public financial accounting experience and is an audit committee financial expert under the SEC rules.
Director Skills
The following matrix highlights the mix of key skills, qualities, attributes, and experiences of the nominees that, among other factors, led the Board and the Nominating Committee to recommend these nominees for election to the Board. The matrix is intended to depict notable areas of focus for each director. This matrix is intended as a high-level summary and not an exhaustive list of each director’s skills or contributions to the Board. Not having a mark does not mean that a particular director does not possess that qualification or skill.
| Howard G. Berger, M.D. |
Laura P. Jacobs |
Lawrence L. Levitt |
A. Gregory Sorensen, M.D. |
Gregory E. Spurlock |
David L. Swartz | |||||||
| Corporate Governance | ● | ● | ● | ● | ● | ● | ||||||
| Financial | ● | ● | ● | ● | ● | ● | ||||||
| Business Operations | ● | ● | ● | ● | ● | ● | ||||||
| Human Capital | ● | ● | ● | ● | ● | ● | ||||||
| Industry Knowledge | ● | ● | ● | ● | ● | ● | ||||||
| Risk Management | ● | ● | ● | ● | ● | ● |
| 17 |
COMPENSATION OF DIRECTORS
Overview of Director Compensation
We use cash and stock based incentive compensation to attract and retain qualified candidates to serve on our Board of Directors. In setting director compensation, we consider the significant amount of time that our directors expend in fulfilling their duties to RadNet as well as the skill level required by the members of our Board of Directors. The Compensation Committee considers and evaluates compensation arrangements and makes recommendations to the Board of Directors, which has ultimate authority to approve such compensation. In addition, our certificate of incorporation and bylaws include indemnification provisions for our directors and executive officers and we maintain liability insurance for our directors and executive officers. Employee directors do not receive any compensation for their service as a director. In accordance with provisions contained in our stockholder-approved Equity Incentive Plan, as amended (the “Equity Incentive Plan”), the maximum total compensation that can be paid to any non-employee director in a calendar year is $500,000.
Annual Compensation for Non-Employee Directors
Based on the recommendation of the Compensation Committee’s independent compensation consultant Pearl Meyer & Partners LLC (“Pearl Meyer”) and their review of peer group data, in January 2024 the Compensation Committee recommended and the Board of Directors approved the following changes to non-employee director compensation effective January 1, 2024 (with all other compensation elements for the non-employee directors remaining unchanged from fiscal year 2023).
| Changes to Non-Employee Director Compensation | Increase in Amount | New Amount | ||||||
| Annual cash compensation retainer | $ | 10,000 | $ | 85,000 | ||||
| Compensation Committee Chair annual cash compensation | $ | 5,000 | $ | 15,000 | ||||
| Lead Independent Director cash compensation | $ | 20,000 | $ | 30,000 | ||||
| Annual equity compensation | $ | 35,000 | $ | 160,000 | ||||
Therefore, effective January 1, 2024, non-employee director compensation was as set forth in the table below and there have been no changes to the below compensation elements as of the date of this proxy statement.
| Annual cash compensation retainer | $ | 85,000 | ||
| Audit Committee Chair annual cash compensation | $ | 20,000 | ||
| Compensation Committee Chair annual cash compensation | $ | 15,000 | ||
| Nominating and Governance Committee Chair annual cash compensation | $ | 10,000 | ||
| Lead Independent Director annual cash compensation | $ | 30,000 | ||
| Committee Meeting Attendance (per meeting) | $ | 1,500 | ||
| Annual equity compensation | $ | 160,000 |
The table below reflects which persons received the above additional non-employee director compensation for service during fiscal 2024.
| Additional Annual Retainers | Name | |
| Lead Independent Director | David Swartz | |
| Audit Committee Chair | David Swartz | |
| Compensation Committee Chair | Lawrence Levitt | |
| Nominating and Governance Committee Chair | Laura Jacobs |
| 18 |
Equity Compensation Awarded in 2024
On June 13, 2024, each of the non-employee directors received a restricted stock award of 2,591 shares of common stock under our Equity Incentive Plan, with a grant date value of approximately $160,000 based on the June 12, 2024 $61.75 per-share closing price of RadNet’s common stock. Subject to continued service, vesting of this stock grant will occur at the end of each non-employee director’s current term which coincides with the Annual Meeting.
Nonqualified Deferred Compensation Arrangements
Non-employee directors are eligible to participate in our Deferred Compensation Plans (as defined below). None of our non-employee directors elected to defer any portion of their 2024 compensation.
Director Compensation
The table below summarizes the compensation received by our non-employee directors for the fiscal year ended December 31, 2024.
| Name | Fees Earned or Paid in Cash ($) | Stock Awards ($)(1) | Total ($) | |||||||||
| Lawrence L. Levitt | 106,750 | 159,994 | 266,744 | |||||||||
| Laura P. Jacobs | 103,000 | 159,994 | 262,994 | |||||||||
| Gregory E. Spurlock | 87,000 | 159,994 | 246,994 | |||||||||
| David L. Swartz | 138,000 | 159,994 | 297,994 | |||||||||
______________________
| (1) | Reflects the restricted stock awards described above in “Equity Compensation” awarded in 2024. In accordance with SEC rules, the amounts shown reflect the aggregate grant date fair value of stock awards granted in 2024 computed in accordance with FASB ASC Topic 718, calculated by multiplying the number of shares subject to the award by the closing price of RadNet’s common stock on the grant date. These are not amounts actually paid to or necessarily realized by the grantee. As of December 31, 2024, each of the above non-employee directors held 2,591 shares of unvested restricted stock and no stock options. |
The table below summarizes the compensation received by our directors who also served as employees (i.e. Dr. Berger, Dr. Sorensen, Ms. Gordon) for the year ended December 31, 2024. These employee directors do not receive any additional compensation for their services as directors. Dr. Berger’s 2024 compensation is shown below in the Summary Compensation Table.
| Name | Fees Earned or Paid in Cash ($) | Stock Awards ($) | All Other
Compensation ($)(1) | Total ($) | ||||||||||||
| Christine N. Gordon(2) (3) | 224,615 | 179,984 | 11,850 | 416,450 | ||||||||||||
| A. Gregory Sorensen, M.D. (2) (4) | 600,000 | 700,005 | 29,486 | 1,329,491 | ||||||||||||
______________________
| (2) | Ms. Gordon and Dr. Sorensen received certain of the following items of other compensation as specified in the below table: (a) an automobile allowance; (b) RadNet paid premiums for coverage under RadNet’s split dollar life insurance plans; (c) a 401(k) retirement plan match from RadNet; (d) RadNet paid premiums for group health insurance (medical, dental and vision) plans; and (e) RadNet paid premiums for life insurance and long-term disability coverage under RadNet’s group life insurance plans. |
| 19 |
| Christine Gordon | A. Gregory Sorensen, M.D. | |||||||
| Auto Allowance | $ | 4,846 | $ | – | ||||
| Split Dollar Life | 1,210 | 482 | ||||||
| 401(k) Matching Contribution | – | 3,450 | ||||||
| Life/Disability Insurance | 281 | 1,140 | ||||||
| Group Health Insurance/COBRA | 5,394 | 24,414 | ||||||
| Wellness | 120 | – | ||||||
| Total | $ | 11,850 | $ | 29,486 | ||||
______________________
| (3) | Ms. Gordon ceased to serve on the Board as of July 27, 2024. Ms. Gordon was an employee (but was not an executive officer) until termination of her employment on July 27, 2024 and the amounts reported in the Fees Earned or Paid in Cash column reflect amounts paid to Ms. Gordon for her services as an employee. Ms. Gordon and RMI were parties to an Amended and Restated Severance Agreement, dated February 24, 2022 (“Gordon Agreement”). Under the Gordon Agreement, after any termination of Ms. Gordon’s employment (except if employment was terminated due to her death), RMI was to pay Ms. Gordon severance compensation in the amount of twenty-four (24) months of her regular base salary plus pay for her continued medical benefits for twenty-four (24) months. No such payments or benefits were provided under the Gordon Agreement since Ms. Gordon’s employment (and service on the Board) was terminated due to her death. As of the end of her service on the Board, Ms. Gordon held 3,229 shares of unvested restricted stock and no stock options. |
| (4) | Dr. Sorensen was appointed to the Board (and also then became a Company executive officer) on August 8, 2023. On June 1, 2020, Dr. Sorensen entered into an employment agreement (with a five year term) with RMI. This employment agreement provides for an annual base salary of $600,000 (which is still his current base salary) and, subject to approval by the Compensation Committee, an annual restricted stock grant (“Restricted Stock Award”), pursuant to the Company’s Equity Incentive Plan, with the number of granted shares determined by dividing Dr. Sorensen’s annual base salary by the grant per share value of such shares. Subject to Dr. Sorensen’s continuous service, each annual Restricted Stock Award incrementally vest by one third (1/3) on each of the first three anniversaries of the applicable Restricted Stock Award grant date. All options, warrants and any other deferred equity compensation then held by Dr. Sorensen which are unvested at the date of the Change in Control will then vest on an accelerated basis. If the Company terminates Dr. Sorensen’s employment without Cause or Dr. Sorensen resigns his employment for Good Reason, then Dr. Sorensen is eligible to receive severance in an aggregate amount equal to his annual base salary. The severance is conditioned upon Dr. Sorensen executing and not revoking a general release of claims and will be paid in substantially equal installments over a twelve month period after termination except that the severance will be made in a single lump sum payment if a Change in Control occurred during the twelve month period preceding Dr. Sorensen’s termination date. On January 9, 2024, the Company granted Dr. Sorensen 19,423 shares of Company common stock and the closing price of a Company common share as reported on Nasdaq on such date was $36.04. Subject to Dr. Sorensen’s continued service, these shares vest in three equal annual installments with one-third vesting on each of March 10th of 2024, 2025, and 2026. On January 8, 2025, the Company granted Dr. Sorensen 11,072 shares of Company common stock and the closing price of a Company common share as reported on Nasdaq on such date was $72.35. Subject to Dr. Sorensen’s continued service, these shares vest in three equal annual installments with one-third vesting on each of March 10th of 2025, 2026, and 2027. As of December 31, 2024, Dr. Sorensen held 36,131 shares of unvested restricted stock and stock options to acquire 62,964 shares. |
| 20 |
The following definitions are contained in Dr. Sorensen’s employment agreement and are summarized below.
Adverse Change in Duties: means an action or series of actions taken by RMI, without Dr. Sorensen’s prior written consent, which results in the below:
| · | A change in Dr. Sorensen’s reporting structure, titles, job duties or job functions which results in a material diminution of his status, control, authority or level of responsibility; |
| · | The assignment to Dr. Sorensen of any positions, duties or responsibilities which are materially inconsistent with Dr. Sorensen’s positions, duties and responsibilities or status with RMI; |
| · | A requirement by RMI that Dr. Sorensen be based or perform his duties anywhere other than (i) where they are currently performed (or within a 25 mile radius of that location), or (ii) at RMI’s corporate office location on the date of the employment agreement; or |
| · | A reduction by RMI in Dr. Sorensen’s base salary. |
Change in Control: has the meaning provided to such term in the Company’s Equity Incentive Plan and it is presently defined as the occurrence of any of the following.
| · | any merger or consolidation in which the Company shall not be the surviving entity (or survives only as a subsidiary of another entity whose stockholders did not own all or substantially all of the common stock in substantially the same proportions as immediately before such transaction); |
| · | the sale of all or substantially all of the Company’s assets to any other person or entity (other than a wholly-owned subsidiary of the Company); |
| · | the acquisition of beneficial ownership of a controlling interest (including power to vote) in the outstanding shares by any person or entity (including a “group” as defined by or under Section 13(d)(3) of the Securities Exchange Act of 1934); |
| · | the dissolution or liquidation of the Company; or |
| · | a contested election of directors, as a result of which or in connection with which the persons who were directors before such election or their nominees cease to constitute a majority of the Board. |
| 21 |
Cause:
| · | Dr. Sorensen’s conviction of (or plea of guilty or nolo contendere to) (A) any felony or (B) any misdemeanor involving fraud or dishonesty in connection with the performance of his duties hereunder or moral turpitude; |
| · | the willful and continued failure of Dr. Sorensen for a total of 10 days (which need not be consecutive days) to substantially perform his duties with the Company (other than any such failure resulting from illness or Disability) after a written demand for substantial performance from the Company is delivered to Dr. Sorensen, which demand specifically identifies the manner in which it is claimed Dr. Sorensen has not substantially performed his duties, or |
| · | Dr. Sorensen has willfully engaged in misconduct which has, or can reasonably be expected to have, a direct and material adverse monetary effect on RMI. |
Disability: shall mean that for a period of at least 120 days during any twelve consecutive month period on account of a mental or physical condition, Dr. Sorensen is unable to perform the essential functions of his job for RMI, with or without reasonable accommodation. The determination of Dr. Sorensen’s Disability shall be made (a) by a medical physician selected or agreed to by RMI or (b) upon mutual agreement of RMI and Dr. Sorensen or his personal representative.
Good Reason: means that Dr. Sorensen voluntarily terminates his employment due to either (i) a material default by RMI in the performance of any of its obligations under the employment agreement, or (ii) an Adverse Change in Duties (as defined above), which default or Adverse Change in Duties remains unremedied by RMI for a period of thirty days following its receipt of written notice thereof from Dr. Sorensen (which notice must be provided to the Company within 45 days of the initial existence of the applicable event and which reasonably describes the facts claimed by Dr. Sorensen to constitute the default or Adverse Change in Duties) (the reasons described in items (i) and (ii) of this paragraph being referred to herein as "Good Reason") and such Good Reason termination is consummated by Dr. Sorensen within 30 business days after the expiration of the Company's 30 day remedy period.
| 22 |
EXECUTIVE OFFICERS
The names of our current executive officers, their ages as of March 31, 2025, and their positions are shown below.
| Name of Executive Officer | Age | Position | Executive Officer Since |
| Howard G. Berger, M.D. | 80 | President, Chief Executive Officer and Chairman of the Board | 1992 |
| Stephen M. Forthuber | 64 | President and Chief Operating Officer - Eastern Operations | 2006 |
| Norman R. Hames | 69 | President and Chief Operating Officer- Western Operations | 1996 |
| Cornelis Wesdorp | 48 | President and Chief Executive Officer- Digital Health | 2024 |
| Mark D. Stolper | 53 | Executive Vice President and Chief Financial Officer | 2004 |
| Mital Patel | 39 | Executive Vice President of Financial Planning and Analysis and Chief Administrative Officer | 2016 |
| Michael N. Murdock | 70 | Executive Vice President, Mergers and Acquisitions | 2007 |
| David J. Katz | 61 | Executive Vice President, Chief Legal Officer and Corporate Secretary | 2020 |
| Ranjan Jayanathan | 69 | Executive Vice President, Chief Information Officer | 2010 |
| A. Gregory Sorensen, M.D. | 63 | Executive Vice President, Chief Science Officer, Director | 2023 |
Biographical summaries of each of our executive officers who are not also members of our Board of Directors are included below.
Stephen M. Forthuber has served as an executive officer of RadNet since our acquisition of Radiologix, Inc. in 2006 and currently serves as our President and Chief Operating Officer-Eastern Operations. He joined Radiologix in January 2000, serving as Regional Director of Operations, Northeast, Regional Vice President of Operations, Northeast, Senior Vice President and Chief Development Officer, and ultimately Chief Operating Officer of Radiologix at the time of the sale to RadNet. Prior to working at Radiologix, Mr. Forthuber was employed from 1982 until 1999 by Per-Se Technologies, Inc. and its predecessor companies, where he had significant physician practice management and radiology operations responsibilities. Mr. Forthuber received a B.A. in Business Administration from the College of William and Mary in Virginia.
Norman R. Hames has served as an executive officer of RadNet since 1996 and currently serves as our President and Chief Operating Officer-Western Operations. Mr. Hames served on RadNet’s Board of Directors from 2000 until his resignation in 2019. Applying his more than 30 years of experience in the industry, Mr. Hames oversees all aspects of our California and Arizona facility operations. Prior to joining RadNet, Mr. Hames was President and Chief Executive Officer of his own company, Diagnostic Imaging Services, Inc., which owned and operated 14 multi-modality imaging facilities throughout Southern California prior to its sale to RadNet. Mr. Hames gained his initial experience in operating imaging centers for American Medical international, or AMI, and was responsible for the development of AMl’s single and multi-modality imaging centers.
Cornelis Wesdorp has served as an executive officer of RadNet since 2024 and currently serves as our President and Chief Operating Officer-Digital Health. Prior to joining RadNet, Mr. Wesdorp served as a Managing Director of the private equity firm Hellman & Friedman in London, where he co-led the EU Operations group since February 2023. From 2017 to 2022 Mr. Wesdorp was an executive with Phillips Group in Amsterdam, starting as an executive vice president overseeing the Diagnostic Imaging businesses before being promoted in 2020 to Phillip’s executive committee with responsibility for overseeing the multi-billion euro Precision Diagnosis Division, focused on diagnostic imaging solutions for health systems including imaging systems, informatics and artificial intelligence. From 2011 to 2016, Mr. Wesdorp was an executive vice president with the private equity firm Bain Capital in London, performing various operating partner roles for portfolio companies. From 2006 to 2011, he served in various management roles with NXP Semiconductor, a semiconductor manufacturing and design company based in Eindhoven, Netherlands. Mr. Wesdorp began his career at McKinsey & Company in Amsterdam. Mr. Wesdorp earned a Masters Degree in Physics from the University of Amsterdam and a PhD in Experimental Atomic Physics from Vrije University in Amsterdam.
| 23 |
Mark D. Stolper has served as our Executive Vice President and Chief Financial Officer since July 2004 and prior to that was an independent member of our Board of Directors. Prior to joining RadNet, Mr. Stolper had diverse experiences in investment banking, private equity, venture capital investing and operations. Mr. Stolper began his career as a member of the corporate finance group at Dillon, Read and Co., Inc., executing mergers and acquisitions, public and private financings, and private equity investments with Saratoga Partners LLP, an affiliated principal investment group of Dillon Read. After Dillon Read, Mr. Stolper joined Archon Capital Partners, which made private equity investments in media and entertainment companies. Mr. Stolper also worked for Eastman Kodak, where he was responsible for business development for Kodak’s Entertainment Imaging subsidiary ($1.5 billion in sales). Mr. Stolper was also co-founder of Broadstream Capital Partners, a Los Angeles based investment banking firm focused on advising middle market companies engaged in financing and merger and acquisition transactions. Mr. Stolper has been a member of the board of directors of Surgalign Holdings, Inc. (NASDAQ: SRGA) since March 2017 and Coherus BioSciences, Inc. (NASDAQ: CHRS) since January 2021. He was a member of the board of directors and audit committee for On Track Innovations, Ltd. (NASDAQ: OTIV) from December 2012 until December 2016. He was also previously a member of the board of directors and audit committee for Metropolitan Health Networks, Inc. (NYSE: MDF) from April 2010 until its sale in December 2012, was a member of the board of directors for a privately held entertainment company providing discount ticketing services and branded event merchandising and was Chairman of the board for a private telemedicine and eHealth provider. Mr. Stolper graduated with a liberal arts degree from the University of Pennsylvania and a finance degree from the Wharton School. Additionally, Mr. Stolper earned a postgraduate Award in Accounting from the University of California, Los Angeles.
Mital Patel has served as our Executive Vice President of Financial Planning and Analysis since 2016 and Chief Administrative Officer since 2021. Mr. Patel directs national budgets and finance, provides counsel regarding corporate acquisitions, and identifies opportunities for the company to deliver cost-effective medical services. His background, experience and insight provide a critical and effective connection between our business units and management team. Mr. Patel began his career at RadNet in 2010. Prior to that time, Mr. Patel served as part of the management team at Truxtun Radiology before its acquisition by RadNet. Mr. Patel earned a B.A. degree in Business Administration, with a concentration Management and Marketing, from California State University in Bakersfield.
Michael N. Murdock has served as our Executive Vice President, Mergers and Acquisitions since 2021. Mr. Murdock joined RadNet in November of 2006 upon the acquisition of Radiologix by RadNet. Mr. Murdock was Senior Vice President and Chief Financial Officer of Radiologix since January 2005. Mr. Murdock has spent the majority of his career in senior financial positions with health care companies, including positions with American Medical International and its successor American Medical Holdings, Inc., a $2.4 billion in revenue publicly traded owner and operator of acute care facilities that was acquired by National Medical Enterprises, now Tenet Healthcare. Mr. Murdock also served as Chief Financial Officer of Physician Reliance Network, Inc., a $398 million in revenue publicly traded physician practice management company, specializing in oncology. In 1999, PRN merged with American Oncology, Inc. to become U.S. Oncology, Inc., the nation’s largest healthcare network dedicated to cancer treatment and research. From 1999 through 2004, Mr. Murdock served as CFO of Dental One, a venture capital-backed owner and operator of 48 dental practices in Texas, Arizona, Colorado, and Utah. Mr. Murdock began his career in 1978 as an auditor with Arthur Andersen after receiving a B.S. degree from California State University, Northridge.
David J. Katz has served as our Executive Vice President and Chief Legal Officer since March 2020. Mr. Katz has served as our Corporate Secretary since April 2021. Mr. Katz joined RadNet from the international law firm Perkins Coie LLP, where he was a partner for 20 years. Mr. Katz was in private practice for 30 years before joining RadNet. Mr. Katz is responsible for overseeing all of RadNet’s legal matters including, without limitation, mergers, acquisitions, securities and joint ventures. Mr. Katz has also served as a Los Angeles County Sheriff Reserve Deputy since 1990 and is a two-time Medal of Valor recipient from the Los Angeles County Sheriff’s Department.
| 24 |
Ranjan Jayanathan currently serves as our Executive Vice President and Chief Information Officer, and also serves as General Manager of eRAD, the Company’s information technology division. Mr. Jayanathan joined RadNet in 2010 from Voyant Health, where he was the General Manager of American operations. Prior to Voyant, he was a member of the executive management team of Dynamic Imaging. During his nine-year tenure at Dynamic Imaging, Mr. Jayanathan managed sales, client services, and solutions architecture. He assisted with Dynamic Imaging’s sale to General Electric in 2007 and its integration into GE’s operations. Prior to Dynamic Imaging, he held various Chief Information Officer and Research and Development positions at Advanced Radiology, Reynolds and Reynolds, and National Medical Computer Services. Mr. Jayanathan earned a degree in electrical engineering from the Massachusetts Institute of Technology.
Our executive officers are appointed by and serve at the discretion of the Board of Directors. There are no family relationships among any of our executive officers and directors. There have been no material proceedings to which any director, executive officer or affiliate of the Company, any owner of record or beneficially of more than five percent of any class of voting securities of the Company, or any associate of any such director, executive officer, affiliate of the Company, or security holder is a party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries. There are no arrangements or understandings with another person pursuant to which any of our executive officers or directors were selected as an executive officer or director. None of our current directors or executive officers have been, during the past 10 years, involved in any legal proceedings required to be disclosed pursuant to Item 401(t) of Regulation S-K.
| 25 |
COMPENSATION DISCUSSION AND ANALYSIS
This Compensation Discussion and Analysis explains the guiding principles and practices upon which our executive compensation program is based and the compensation paid to our fiscal year 2024 named executive officers (who consist of our principal executive officer, principal financial officer and our next three most highly compensated executive officers in fiscal year 2024 and such persons are referred to as our “Named Executive Officers”):
Howard G. Berger, M.D. - President and Chief Executive Officer (our principal executive officer)
Mark D. Stolper - Executive Vice President and Chief Financial Officer (our principal financial officer)
Cornelis Wesdorp - President and Chief Executive Officer of Digital Health
Stephen M. Forthuber - President and Chief Operating Officer - Eastern Operations
Norman R. Hames - President and Chief Operating Officer - Western Operations
Our executive compensation program is designed to attract, retain and motivate talented executive officers who are capable of providing leadership, vision and execution necessary to achieve our business objectives. We actively seek to align the interests of our Named Executive Officers with the creation of stockholder value through our equity compensation program. We believe the compensation paid to our Named Executive Officers for the year ended December 31, 2024 appropriately reflects and rewards their contribution to our performance.
In 2024, the Company enjoyed a successful year with continued positive financial results and increased demand in virtually all of its markets. This demand was the primary catalyst for the investments made to expand capacity by the opening of nine new centers during the year. Throughout 2024, the centers within health system partnerships grew from 130 at the beginning of 2024 to 153 by the end of the year. Moreover, for 2024, the Company finished the year with total revenue of $1.83 billion which was an increase of 13.2% over 2023 total revenue and income from operations increased by 6% to $104.6 million. Executive management played a critical role in generating the foregoing accomplishments.
Compensation Philosophy
The following principles influence and guide the compensation decisions of the Compensation Committee:
Our Management Team is Integral to our Success. At the core of our compensation philosophy is the guiding belief that our management team is an integral component to RadNet’s continued success. Equity compensation and cash bonuses are generally determined near the end of the calendar year and are paid at the beginning of the fiscal year with the goal of continuing to retain and incentivize our Named Executive Officers to achieve or exceed the strategic initiatives set for the upcoming year.
Compensation Decisions Should Promote the Interests of Stockholders. Compensation should create incentives for management to achieve strong short-term (annual) performance in a manner that supports and ensures our long-term success and profitability. The Compensation Committee believes that performance-based equity incentive awards, stock option and/or restricted stock awards (or restricted stock units (“RSUs”)) create long-term incentives that align the interests of management with the long-term interests of stockholders.
Compensation Should Reflect Position and Responsibility. Total compensation and accountability should generally increase with position and responsibility. Consistent with this philosophy: (a) total compensation is higher for individuals with greater responsibility and greater ability to influence RadNet’s achievement of targeted results and strategic initiatives; and (b) equity-based compensation is higher for persons with higher levels of responsibility, making a significant portion of their total compensation dependent on long-term stock appreciation.
| 26 |
Internal Pay Equity. We have not established a formal policy regarding the ratio of total compensation of the Chief Executive Officer to that of the other officers, but the Compensation Committee believes that internal pay equity is an important factor to be considered in establishing compensation for our Named Executive Officers, and reviews compensation levels to ensure that appropriate pay equity exists.
Compensation Should be Reasonable and Responsible. It is essential that our overall compensation levels be sufficiently competitive to attract and retain talented leaders and motivate those leaders to achieve superior results. At the same time, we believe that compensation should be set at responsible levels and the Compensation Committee periodically reviews market information from external sources or advisors to determine appropriate levels. Our executive compensation programs are intended to be consistent with our focus on controlling costs.
Compensation Disclosures Should be Clear and Complete. The Compensation Committee and management believe that all aspects of executive compensation should be clear, comprehensible and promptly disclosed in plain English. The Compensation Committee and management believe that compensation disclosures should provide all of the information necessary to permit stockholders to understand our compensation philosophy, our compensation-setting process and how much our Names Executive Officers are paid.
Board and Committee Process
The Role of the Compensation Committee
Our Board of Directors has delegated to the Compensation Committee the authority to approve all compensation and awards to Named Executive Officers. With respect to equity compensation awarded to the Named Executive Officers and others, the Compensation Committee acts as the administrator under the Equity Incentive Plan, and has the authority under that plan to grant equity compensation awards, including restricted stock, RSUs and stock options.
Our Compensation Committee meets as often as necessary to perform its duties and responsibilities. The Committee meets with its compensation consultant and, as applicable, executive management, including our Chief Executive Officer. The Compensation Committee meets in executive session each year to: (a) evaluate the performance of the Named Executive Officers, (b) set the annual compensation of the Named Executive Officers, and (c) consider and approve any grants of equity incentive compensation to the Named Executive Officers.
The Compensation Committee has ultimate authority, including delegated authority over all aspects of Named Executive Officer compensation, including the base salary for each Named Executive Officer and the overall compensation of the Chief Executive Officer.
The Role of Management in the Compensation-Setting Process
Management’s role in the compensation-setting process, includes the following:
establishing the operating budget approved by the Board of Directors, which forms the basis for evaluating corporate achievements and the achievements of the divisions our Named Executive Officers manage that are taken into consideration when evaluating compensation levels for Named Executive Officers;
making recommendations to the Compensation Committee on salary levels and performance-based equity incentive awards, stock option and restricted stock awards (or RSUs); and
allocating the amount of cash bonus, restricted stock (or RSUs) and stock option amounts to be awarded to our Named Executive Officers.
| 27 |
Management also prepares information for Compensation Committee meetings. Our Chief Executive Officer (or other executive officers) also participate in committee meetings at the request of the Compensation Committee to provide, among other things:
| · | background information regarding RadNet’s strategic objectives; and | |
| · | his evaluation of the performance of the other Named Executive Officers, including accomplishments, and areas of strength and weakness. |
The Role of the Compensation Consultant
Under its charter, the Compensation Committee is granted the authority to retain outside advisors and compensation consultants. The Compensation Committee has retained Pearl Meyer to serve as its independent outside compensation consultant and provide compensation analysis and advice since 2016. Pearl Meyer provides the following services with respect to compensation determinations:
| · | Executive compensation benchmarking and framework; | |
| · | Assessment of market trends of non-employee director compensation; | |
| · | Review of market compensation practices and trends; | |
| · | Annual incentive plan and equity award design; | |
| · | Advice on merit increases, target bonuses and equity award levels; | |
| · | Assessment of employment and Change in Control agreement provisions; and | |
| · | Legislative and regulatory updates. |
Pearl Meyer attends certain Compensation Committee meetings in person or by telephone, including executive sessions as requested, and consults with the Compensation Committee Chair. Pearl Meyer also reviewed and commented on this executive compensation disclosure and the Named Executive Officer and director compensation tables contained in this Proxy Statement.
As part of the selection and retention process, the Compensation Committee analyzes the independence of Pearl Meyer under SEC and Nasdaq Rules. Pearl Meyer reports directly to the Compensation Committee and performs no other work for RadNet besides rendering compensation consulting services.
In accordance with its charter, the Compensation Committee analyzed whether the work of Pearl Meyer as a compensation consultant has raised any conflict of interest, taking into consideration the following factors: (a) the provision of other services to RadNet by Pearl Meyer; (b) the amount of fees from RadNet paid to Pearl Meyer as a percentage of the firm’s total revenue; (c) Pearl Meyer’s policies and procedures that are designed to prevent conflicts of interest; (d) any business or personal relationship of Pearl Meyer or the individual compensation advisors employed by the firm with an executive officer of RadNet; (e) any business or personal relationship of the individual compensation advisors with any member of the Compensation Committee; and (f) any stock of RadNet owned by Pearl Meyer or the individual compensation advisors employed by the firm. The Compensation Committee has determined, based on its analysis of the above factors, that the work of Pearl Meyer and the individual compensation advisors employed by Pearl Meyer as compensation consultants to RadNet has not created a conflict of interest.
| 28 |
The Role of Peer Companies and Benchmarking
The Compensation Committee reviews a peer group of companies (“Peer Group”) recommended by Pearl Meyer in order to assess the competitiveness of our executive officer compensation level and structure. The composition of the Peer Group is reviewed periodically.
In November 2023, Pearl Meyer provided the Compensation Committee with a compensation benchmarking report on the Company’s Peer Group along with a recommended new Peer Group for fiscal year 2024 after review of U.S. publicly traded companies with annual revenue, EBITDA, Net Income, market capitalization, and enterprise value approximately one-third to twice RadNet’s annual revenue whose primary operations are in the healthcare facility and services industry. The Compensation Committee approved the proposed fiscal year 2024 Peer Group and this peer group consisted of the following companies:
| Acadia Healthcare Company, Inc. | AdaptHealth Corp | Addus HomeCare Corporation |
| Amedisys, Inc. | Astrana Health, Inc. | Aveanna Healthcare Holdings Inc. |
| InnovAge Holding Corp. | ModivCare Inc. | Option Care Health, Inc. |
| Pediatrix Medical Group, Inc. | Select Medical Holdings Corporation | Surgery Partners, Inc. |
| The Ensign Group, Inc. | U.S. Physical Therapy, Inc. |
Elements of Executive Compensation
Base Salary
We seek to establish a base salary compensation level that appropriately recognizes each Named Executive Officer’s achievements and contributions. Base salary also provides executives with a secure level of income that is not at risk, and our Compensation Committee believes that this gives our Named Executive Officers the ability to focus on the longer term and avoid the urgency that could otherwise encourage a Named Executive Officer to take unnecessary risks. In determining base salaries, our Compensation Committee considers the Named Executive Officer’s qualifications and experience, scope of responsibilities and future potential, the executive’s ability to influence RadNet’s achievements of targeted results and strategic initiatives, the goals and objectives established for the Named Executive Officer, the Named Executive Officer’s past performance, the general pay practices at other companies in our Peer Group, internal pay equity and the tax deductibility of base salary.
Discretionary Cash Bonuses
In recent years, the Compensation Committee has elected to supplement base salary and equity-based compensation with discretionary cash bonus awards generally paid in the beginning of the fiscal year. These discretionary cash bonuses are awarded with the goal of continuing to retain and incentivize our Named Executive Officers to achieve or exceed the strategic initiatives set for the upcoming year.
Equity Based Compensation
We believe that equity compensation is the most effective means of aligning the interests of our officers and other key management personnel with gains realized by our stockholders. The Compensation Committee uses equity awards, including performance-based equity incentive awards, restricted stock, RSUs and stock options, as a long-term incentive vehicle because:
performance-based equity incentive awards align the interests of executives with those of our stockholders while encouraging objective strategic goals established by the Compensation Committee;
| 29 |
restricted stock, RSUs and/or stock options align the interests of executives with those of our stockholders, support a pay-for-performance culture, foster employee stock ownership and focus the management team on increasing value for our stockholders; and
the vesting period encourages executive retention and the creation of stockholder value.
We use a mix of performance-based equity awards, restricted stock, RSUs and/or stock options for equity compensation grants to the Named Executive Officers. In determining the maximum number of performance-based equity awards shares of restricted stock, RSUs and stock options to be granted to Named Executive Officers, the Compensation Committee considers the individual’s position, scope of responsibility, ability to affect profits and stockholder value and the individual’s historic and recent performance, the value of the equity awards in relation to other elements of total compensation, internal pay equity and market competitiveness. While there is no formal written policy about the timing and frequency of equity compensation awards, the Compensation Committee has historically issued annual equity grants to the named executive officers during the first ten days of January and further information about our equity grant practices is provided under the Equity Award Grant Practices section. The Chief Executive Officer considers similar factors when allocating the number of shares of performance-based equity awards, restricted stock, RSUs and stock options to be granted to the senior executive officers, within the limitations set by the Compensation Committee.
Our Equity Incentive Plan was most recently approved by our stockholders at our annual stockholders meeting on June 7, 2023. Unless terminated earlier, the Equity Incentive Plan will terminate on April 26, 2033. The Equity Incentive Plan permits the discretionary award of incentive stock options (“ISOs”), nonqualified stock options (“NSOs”), stock appreciation rights (“SARs”), restricted stock, and RSUs. Directors, officers, employees and consultants of RadNet and certain of our affiliated companies are eligible to receive awards under the Equity Incentive Plan. Certain other key features of the Equity Incentive Plan are summarized as follows:
Up to a maximum aggregate of 20,100,000 common shares may be issued under the Equity Incentive Plan. As of December 31, 2024, 3,172,578 common shares were available for potential future issuance (which excludes 358,549 shares subject to outstanding RSUs).
The aggregate value of compensation, including awards granted to any individual non-employee director during any calendar year, may not exceed $500,000.
The Equity Incentive Plan will generally be administered by a committee comprised solely of independent members of the Board, such as the Compensation Committee (the “Plan Administrator”). The Board or Plan Administrator may designate a Company officer to make awards (within parameters established by the Board) to employees who are not officers subject to the reporting requirements of Section 16 of the Exchange Act or are not Code Section 162(m) Covered Employees.
The Plan Administrator has the discretion to determine who shall receive any Plan awards and the terms and condition of such awards.
Stock options and stock appreciation rights may not be granted at a per share exercise price below the fair market value of a share of our common stock on the date of grant.
Stock options and stock appreciation rights may not be repriced or exchanged without stockholder approval. The maximum exercisable term of stock options and stock appreciation rights may not exceed ten years.
Awards are subject to recoupment of compensation policies (referred to as clawback policies) which have been adopted (including without limitation, the Company’s Policy on Recovery of Erroneously Awarded Compensation as adopted by the Board on November 8, 2023 and as may be amended from time to time by the Company) or which may be adopted by the Company in the future.
| 30 |
Additional Benefits
Our executive officers, including our Named Executive Officers, participate in other employee benefit plans generally available to all employees on the same terms as similarly situated employees. Perquisites to our Named Executive Officers are not a material element of our compensation program. We pay the premiums for our Named Executive Officers’ coverages under our health and life insurance plans and all of our Named Executive Officers are provided either an automobile allowance, the use of a Company-provided automobile or Company reimbursement for certain automobile expenses. We also maintain a Split Dollar Life Insurance Plan pursuant to which we have corporate owned life insurance (“COLI”) policies on our key management employees including our Named Executive Officers. These COLI policies would, upon the insured’s death, pay death benefits proceeds to the insured’s beneficiaries while RadNet would then receive any excess death benefit proceeds along with any remaining cash surrender value of the COLI policy. Each Named Executive Officer has executed a participation agreement with RadNet under the Split Dollar Life Insurance Plan, which agreement specifies the amount of death benefit proceeds and the beneficiaries of this life insurance arrangement. Additionally, we have historically provided matching 40l(k) contributions for our employee participants, which we suspended in 2020 but commenced providing again in 2021 and continued to provide in 2024.
Change in Control and Severance Arrangements
As described in the “Employment Agreements” section below, as an inducement to attract and retain qualified executive officers, certain benefits are provided if the Named Executive Officer’s employment is terminated under certain circumstances (other than for Mr. Wesdorp). None of our Named Executive Officers are eligible for gross-up payments to cover excise taxes in connection with a change in control transaction. There is full acceleration of time-based vesting for all then-unvested shares underlying equity compensation awards issued under the Equity Incentive Plan and the Deferred Compensation Plans upon termination of a participant’s service due to his/her death or disability. Such accelerated vesting is also provided to the Named Executive Officers upon a change in control or upon a qualifying involuntary termination of employment.
Nonqualified Deferred Compensation Arrangements
We maintain a Nonqualified Deferred Compensation Plan (the “NDC Plan”) and a RadNet Deferred Compensation Plan (2016) (the “Excess Plan” and together with the NDC Plan, the “Deferred Compensation Plans”) which are administered by the Compensation Committee. The NDC Plan is used for the deferral of equity compensation and the Excess Plan is used for the deferral of cash compensation. The Named Executive Officers, the members of the Board of Directors, and other executives or highly compensated employees of RadNet or designated affiliated entities (collectively, “participants”) who are selected by the Compensation Committee are eligible to participate in the Deferred Compensation Plans. Participants have the opportunity to voluntarily elect to defer the timing of payment of base salary, incentive compensation and/or stock awards. The Compensation Committee determines which forms of compensation are eligible for deferral and can prescribe limits on the amount of deferrals. It may also, in its discretion, credit a participant’s account with a contribution amount from RadNet.
Cash-based deferrals may also accrue notional investment returns based on the performance of one or more measurement funds selected by RadNet and in which the participant may elect to have portions of his/her cash account hypothetically invested. RadNet stock grant deferrals will be settled on a one-for-one basis with RadNet common shares (or their cash equivalent). The Deferred Compensation Plans are not funded; payments are made out of RadNet’s general assets and participants are unsecured general creditors of RadNet with respect to deferred amounts. However, as expressly permitted under the Deferred Compensation Plans and applicable tax laws, RadNet has established a “rabbi trust” to provide a source of funds for meeting its financial obligations under the Deferred Compensation Plans.
Participants generally must submit their elections to defer compensation before the calendar year in which compensation is earned (except that participants can make a deferral election within 30 days of their initial eligibility to participate in the Deferred Compensation Plans). Settlement of deferred amounts will be affected in accordance with the Deferred Compensation Plans and the applicable deferral election and generally will be paid in either a lump sum or a series of annual installments after the applicable distribution date. Deferred compensation amounts can be paid out on an accelerated basis under certain circumstances including a change in control of RadNet. The aggregate amount that could potentially be paid out under the Deferred Compensation Plans is presently indeterminable and will depend on the amounts and types of deferrals along with the performance of the hypothetical investments and RadNet stock value.
| 31 |
The Deferred Compensation Plans are each intended to be a “top-hat” plan and are governed by the laws of the state of Delaware except to the extent preempted by The Employee Retirement Income Security Act of 1974. It is intended that the Deferred Compensation Plans and any payments thereunder comply with Internal Revenue Code (“Code”) Section 409A, which governs the federal income taxation of nonqualified deferred compensation. The Deferred Compensation Plans will remain in effect until terminated by RadNet, but deferred amounts may still, in certain circumstances, remain outstanding in accordance with the applicable deferral elections after termination.
Insider Trading Policy
Our Board adopted an Insider Trading Policy governing the purchase, sale and other dispositions of the Company’s securities that applies to directors, officers, employees and consultants that are aware of certain material, non-public information. We believe our Insider Trading Policy are reasonably designed to promote compliance with insider trading laws, rules and regulations, and the listing standards applicable to the Company. A copy of the Company’s Insider Trading Policy was filed as Exhibit 19.1 to our Amendment No. 1 to the Form 10-K for the year ended December 31, 2024.
Policy Prohibiting Hedging and Pledging
Our insider trading policy prohibits employees, advisors, officers, directors and consultants of the Company, members of their immediate families, and corporations, partnerships or similar entities which such persons influence or control (collectively, “Covered Persons”) from entering into hedging or derivative transactions, including purchasing financial instruments (such as prepaid variable forward contracts, equity swaps, collars, and exchange funds), or otherwise engage in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of the Company’s securities. Our Chief Legal Officer, who serves as chief compliance officer under the policy, has the authority to grant exceptions to the prohibition against pledges where a Covered Person wishes to pledge Company securities as collateral for a loan (not including margin debt) and clearly demonstrates the financial capacity to repay the loan without resort to the pledged securities.
Equity Award Grant Practices
Currently, our equity compensation awards to the executive officers, including Named Executive Officers, including stock options (if any), are granted near the start of the new fiscal year, typically in the first ten days of January, to incentivize our executives and to deliver on the Company’s strategic objectives for the new fiscal year, with the Compensation Committee approving such awards at a regularly scheduled meeting. Our equity compensation awards to non-employee directors are granted typically on the date of our Annual Meeting of Stockholders. Our equity compensation awards to non-executive employees are granted typically during the first quarter of the new fiscal year. The Compensation Committee (which can approve equity compensation awards to executive officers and other service providers) and the Board (which can approve equity compensation awards to non-employee directors and other service providers) do not take material nonpublic information into account when determining the timing of grant or the terms of equity compensation awards. Moreover, equity compensation awards, including stock options, are not granted in anticipation of the release of material non-public information, and the release of material non-public information is not timed on the basis of option or other equity grant dates. The Company considers making grants to executive officers, non-employee directors, and non-executive employees outside of the time periods mentioned above in cases of new hires, promotions and other special situations. Our Compensation Committee and Board continually evaluate our equity award grant practices to maintain our competitiveness and to align with current practices in the market. As such, our equity award grant practices may change in the future.
In 2024, no equity awards were granted to Named Executive Officers outside of January 2024 other than the equity awards issued to Mr. Wesdorp upon his commencement of service in October 2024. During fiscal year ending December 31, 2024, the Company did not grant equity awards to any Named Executive Officers during any period beginning four business days before and ending one business day after the filing of any Company periodic report on Form 10-Q or Form 10-K, or the filing or furnishing of any Form 8-K that disclosed any material non-public information. No stock options, stock appreciation rights, or similar option like equity awards have been granted to any Named Executive Officer since January 2023.
| 32 |
Fiscal Year 2024 Compensation Determinations
As noted above in The Role of Peer Companies and Benchmarking section, the Compensation Committee received a compensation benchmarking report from Pearl Meyer on the Company’s Peer Group for 2024. Based in part on this report, and after considering each executive’s contribution to the Company’s growth and record AEBITDA performance, the Compensation Committee elected to (a) modify base salaries for the Named Executive Officers as shown in the below table and (b) make certain other compensation decisions set forth below for 2024. Mr. Wesdorp did not join RadNet until October 2024 and therefore was not considered in these compensation adjustments and incentives.
Increase in Base Salary | Base Salary as of January 1, 2024 | |||||||
| Howard Berger | $ | 1,500,000 | $ | 3,000,000 | ||||
| Mark Stolper | $ | 125,000 | $ | 700,000 | ||||
| Norman Hames | $ | 150,000 | $ | 800,000 | ||||
| Stephen Forthuber | $ | 150,000 | $ | 800,000 | ||||
The increases in base salary were reflective of the continuing superior Company performance including the fiscal year 2023 financial results. In the case of the Chief Executive Officer, the increase in base salary was in part to compensate him for the many years in which he received no equity compensation and in which his total compensation was below the median of chief executive officers in our peer group.
On January 9, 2024, in order to retain and further motivate the Named Executive Officers and align their interests with Company stockholder interests, the Compensation Committee determined to provide the Named Executive Officers with the cash bonuses which were paid in January 2024 in the amount of $4,000,000, $575,000, $650,000, and $650,000, for Messrs. Berger, Stolper, Hames, and Forthuber, respectively. The bonuses paid to the Named Executive Officers (other than the Chief Executive Officer) were equal to 100% of 2023 base salaries. Dr. Berger’s cash bonus amount was paid by BRMG. In addition, the Compensation Committee determined to eliminate the portion of long-term incentives previously granted in stock options, PSOs and PSUs after a careful review of which equity vehicle would best motivate executives to achieve the strategic plan and encourage a rapid and effective response given the Company’s opportunities for growth. The Compensation Committee determined to provide the Named Executive Officers with grants of stock units (for those Named Executive Officers deferring receipt of the underlying shares) or restricted shares (for those Named Executive Officers who are not deferring receipt of the underlying shares) (either “RSG Shares”) with a grant date value approximately equal to 100% of the 2023 base salaries for the Named Executive Officers (other than for the Chief Executive Officer). These amounts compare to the 2023 equity award values for the Named Executive Officers (other than for the Chief Executive Officer) of 175% of salary as outlined above. Moreover, the grant date values of the 2024 equity compensation awards to each Named Executive Officer is materially lower than the grant date values of their 2023 equity compensation awards. The table below reflects the 2024 awards.
| Target Value of RSGs | Number of RSG Shares(1) | |||||||
| Howard Berger | $ | 2,000,000 | 55,494 | |||||
| Mark Stolper | $ | 575,000 | 15,954 | |||||
| Norman Hames | $ | 650,000 | 18,036 | |||||
| Stephen Forthuber | $ | 650,000 | 18,036 | |||||
| Total | $ | 3,875,000 | 107,520 | |||||
______________________
| (1) | The number of RSG Shares is equal to the whole number (rounded to the nearest integer) that is the quotient of the grant dollar value shown above divided by the closing price of a Company common share as reported on Nasdaq for January 9, 2024 which was $36.04. Subject to the Named Executive Officer’s continued service, the RSG Shares vest in three equal annual installments with one-third vesting on each of March 10, 2024, March 10, 2025 and March 10, 2026. |
| 33 |
Stockholder Advisory Votes on Executive Compensation
In June 2023, approximately 88% of the stockholder votes (excluding abstained and broker non-votes) were cast “FOR” the stockholder advisory vote regarding our Named Executive Officers’ compensation. In June 2024, approximately 89% of the stockholder votes (excluding abstained and broker non-votes) were cast “FOR” the stockholder advisory vote regarding our Named Executive Officers’ compensation. The Compensation Committee carefully considered these results and a variety of other information, including the most recent competitive market assessment of pay, in determining compensation structure and amounts for each of 2024 and 2025, respectively.
Fiscal Year 2025 Compensation Determinations
In November 2024, Pearl Meyer provided the Compensation Committee with a compensation benchmarking report on the Company’s Peer Group along with a recommended new Peer Group for fiscal year 2025 after review of U.S. publicly traded companies with annual revenue, EBITDA, Net Income, market capitalization, and enterprise value approximately one-third to twice RadNet’s annual revenue whose primary operations are in the healthcare facility and services industry. The Compensation Committee approved this new Peer Group which consists of the following companies:
| Acadia Healthcare Company, Inc. | AdaptHealth Corp | Addus HomeCare Corporation |
| Amedisys, Inc. | Astrana Health, Inc. | Aveanna Healthcare Holdings Inc. |
| Chemed Corporation | Concentra Group Holdings Parent, Inc. | Encompass Health Corporation |
| Option Care Health, Inc. | PACS Group, Inc. | Pediatrix Medical Group, Inc. |
| Select Medical Holdings Corporation | Surgery Partners, Inc. | The Ensign Group, Inc. |
| U.S. Physical Therapy, Inc. |
Based in part on this report, and after considering each executive’s contribution to the Company’s growth and AEBITDA performance, the Compensation Committee elected to not modify base salaries for the Named Executive Officers (which had been last adjusted effective January 1, 2024) but did make certain other compensation decisions set forth below for 2025 in recognition of the superlative Company performance in 2024.
On January 8, 2025, the Compensation Committee determined to provide the Named Executive Officers (other than Mr. Wesdorp who was not eligible for a bonus for 2024) with the cash bonuses (which were paid in January 2025) in the amount of $350,000, $400,000, and $400,000, for Messrs. Stolper, Hames, and Forthuber, respectively. The bonuses paid to these Named Executive Officers were equal to 50% of their 2024 annual base salaries. Additionally, on January 8, 2025, in order to retain and further motivate the Named Executive Officers enumerated below and align their interests with Company stockholder interests, the Compensation Committee determined to provide the following Named Executive Officers with grants of stock units (for those Named Executive Officers deferring receipt of the underlying shares) or restricted shares (for those Named Executive Officers who are not deferring receipt of the underlying shares) (either, “RSG Shares”) with a grant date value approximately equal to 250% of the 2024 annual base salaries for the Named Executive Officers (other than for the Chief Executive Officer whose grant date value was equal to 300% of his 2024 annual base salary). The table below reflects the 2025 awards.
| Grant Date Value of RSGs | Number of RSG Shares(1) | |||||||
| Howard Berger | $ | 9,000,000 | 124,567 | |||||
| Mark Stolper | $ | 1,750,000 | 24,221 | |||||
| Norman Hames | $ | 2,000,000 | 27,681 | |||||
| Stephen Forthuber | $ | 2,000,000 | 27,681 | |||||
| Total | $ | 14,750,000 | 204,150 | |||||
______________________
| (1) | The number of RSG Shares is equal to the whole number (rounded to the nearest integer) that is the quotient of the grant dollar value shown above divided by the closing price of a Company common share as reported on Nasdaq for January 8, 2025 which was $72.35. Subject to the Named Executive Officer’s continued service, the RSG Shares vest in four annual installments with 20% vesting on March 10, 2025 and the remaining 80% vesting in three equal installments on each of March 10, 2026, March 10, 2027 and March 10, 2028. |
| 34 |
Taxes, Risks and other Considerations
Tax Deductibility of Compensation
Section 162(m) of the Internal Revenue Code generally places a $1 million limit on the amount of compensation a publicly held company can deduct in any tax year on compensation paid to “covered employees.” The Compensation Committee considers tax deductibility as one of many factors in determining executive compensation, including the impact of these tax law changes. However, the Compensation Committee believes that in certain circumstances factors other than tax deductibility take precedence when determining the forms and levels of executive compensation most appropriate and in our best interest and the best interest of our stockholders. Thus, executive compensation arrangements may not be tax deductible or, if initially intended to be tax deductible, may not actually receive this treatment.
Risk Considerations in Our Compensation Programs
Our Compensation Committee reviews the concept of risk as it relates to our compensation program and does not believe our compensation program encourages excessive or inappropriate risk taking. The Compensation Committee believes our compensation programs strike a balance between providing secure compensation (base salaries) as well as appropriate short- and long-term incentives, such that our executive officers are not encouraged to take unnecessary or excessive risks.
Stock Ownership
We structure our pay to consist of primarily fixed compensation with base salary in cash, bonuses and non-cash long-term incentive programs. Although we do not have requirements or guidelines specifying amounts of ownership of RadNet common stock for our Named Executive Officers, we do promote and encourage the aligning of their interests with those of our stockholders by providing them with significant equity awards.
Recoupment of Erroneously Awarded Compensation Policy
In November 2023, our Board of Directors adopted a Policy on Recovery of Erroneously Awarded Compensation or “Clawback Policy” that is intended to deter both financial/accounting irregularities with respect to RadNet’s financial statements and also misconduct by senior executives. The Clawback Policy is intended to comply with the listing rules of the Nasdaq Stock Market LLC and SEC Exchange Act Rule 10D-1. The Clawback Policy is generally administered by the Compensation Committee although the Board of Directors may administer the policy or designate another committee to serve in such role, and may also act in conjunction with the Audit Committee. The policy applies to RadNet’s officers and other designated key employees (collectively, “Senior Executives”).
Under the Clawback Policy, if RadNet is required to restate any financial statements (other than due to a change in accounting policy), then the Compensation Committee (or other designated committee) can take certain actions to recoup performance-based compensation from the Senior Executives that exceeded the amount that would have been paid under the restated financial results, including the cancellation of equity compensation awards. Performance-based compensation that was paid, vested or earned in the three most recent completed fiscal years prior to (a) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an accounting restatement or (b) the date a court, regulator or other legally authorized body directs the Company to prepare an accounting restatement, in each case regardless of if or when the restated financial statements are filed is generally subject to recoupment. A Senior Executive that is determined to have committed “Misconduct” (as defined under the Clawback Policy) is subject to additional measures including recoupment or cancellation or reimbursement of incentive compensation, adjustment of future compensation, and/or disciplinary actions including termination of employment.
| 35 |
COMPENSATION COMMITTEE REPORT*
The Compensation Committee has reviewed and discussed with RadNet’s management the “Compensation Discussion and Analysis” included above and unanimously recommended to the Board of Directors that the “Compensation Discussion and Analysis” be included in this Proxy Statement and the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
Submitted by the Compensation Committee:
Lawrence L. Levitt, Chair
Laura P. Jacobs
Gregory E. Spurlock
David L. Swartz
_______________
* The material in this report is not “soliciting material,” is not deemed filed with the SEC and is not to be incorporated by reference into any of our filings under the Securities Act or the Exchange Act whether made before or after the date of this Proxy Statement and irrespective of any general incorporation language therein.
Compensation Committee Interlocks and Insider Participation
The members of our Compensation Committee are Lawrence L. Levitt, Laura P. Jacobs, Gregory E. Spurlock, and David L. Swartz. None of our executive officers serve or have served on the board of directors or compensation committee of another company that also has an executive officer that serves on our board of directors or our Compensation Committee.
| 36 |
EXECUTIVE COMPENSATION TABLES
Summary Compensation Table
The following table, footnotes and related narrative summarizes the total compensation paid to or earned by each of our Named Executive Officers for fiscal years 2024, 2023, and 2022:
| Name and Principal Position | Year | Salary($) | Bonus($) | Stock Awards ($) (1) | Option Awards ($) (1) | All Other Compensation ($)(2) | Total($) | ||||||||||||||||||||
| Howard G. Berger, M.D. | 2024 | 3,000,000 | 4,000,000 | 2,000,004 | – | 76,433 | 9,076,437 | ||||||||||||||||||||
| President and Chief Executive Officer | 2023 | 1,500,000 | 2,000,000 | 1,375,000 | 1,750,000 | 75,183 | 6,700,183 | ||||||||||||||||||||
| (principal executive officer)(3) | 2022 | 1,500,000 | 4,000,000 | – | – | 55,517 | 5,555,517 | ||||||||||||||||||||
| Mark D. Stolper | 2024 | 700,000 | 575,000 | 574,982 | – | 33,157 | 1,883,139 | ||||||||||||||||||||
| Executive Vice President and | 2023 | 575,000 | 287,500 | 431,250 | 575,000 | 31,954 | 1,900,704 | ||||||||||||||||||||
Chief Financial Officer (principal financial officer) | 2022 | 575,000 | 525,000 | 681,250 | 825,000 | 31,213 | 2,637,463 | ||||||||||||||||||||
| Cornelis Wesdorp (4) | 2024 | 153,341 | – | 4,160,469 | – | 13,595 | 4,327,405 | ||||||||||||||||||||
| President and Chief Executive Officer of Digital Health | |||||||||||||||||||||||||||
| Stephen M. Forthuber | 2024 | 800,000 | 650,000 | 650,017 | – | 52,882 | 2,152,899 | ||||||||||||||||||||
| President and Chief Operating | 2023 | 650,000 | 325,000 | 487,500 | 650,000 | 48,065 | 2,160,565 | ||||||||||||||||||||
| Officer - Eastern Operations | 2022 | 650,000 | 600,000 | 775,000 | 937,500 | 47,258 | 3,009,758 | ||||||||||||||||||||
| Norman R. Hames | 2024 | 800,000 | 650,000 | 650,017 | – | 36,486 | 2,136,503 | ||||||||||||||||||||
| President and Chief Operating | 2023 | 650,000 | 325,000 | 487,500 | 650,000 | 30,460 | 2,142,960 | ||||||||||||||||||||
| Officer - Western Operations | 2022 | 650,000 | 600,000 | 775,000 | 937,500 | 26,776 | 2,989,277 | ||||||||||||||||||||
______________________
| (1) | The value for the stock awards is based on the number of shares granted multiplied by the closing share price of our common stock on the date of grant. These are not amounts actually paid to or realized by the Named Executive Officer. |
| (2) | For 2024, some of the Named Executive Officers received certain of the following items of other compensation as specified in the following table: (a) an automobile allowance; (b) RadNet paid premiums for coverage under RadNet’s split dollar life insurance plans; (c) a 401(k) retirement plan match from RadNet; (d) RadNet paid premiums for group health insurance (medical, dental and vision) plans; and (e) RadNet paid premiums for life insurance and long-term disability coverage under RadNet’s group life insurance plans. In addition, Mr. Wesdorp received a homework and holiday allowance. In the Netherlands, (i) employers can offer a tax-free "homework allowance" to employees who work from home, compensating for additional costs like heating and electricity and (ii) employees are required by law to receive at least 8% of their salary as a holiday allowance. |
In 2024, Dr. Berger and Mr. Hames utilized RadNet-provided automobiles for which it was estimated that thirty percent was used for personal purposes and RadNet also paid for automobile insurance costs. The below figures (which are all in US dollars) reflect the estimated incremental cost incurred by RadNet for the personal usage by Dr. Berger and Mr. Hames of such RadNet-provided automobiles.
| 37 |
| Howard Berger | Mark Stolper | Cornelis Wesdorp | Stephen Forthuber | Norman Hames | ||||||||||||||||
| Auto Allowance | – | 9,600 | – | 15,000 | – | |||||||||||||||
| Company-provided Automobile | 15,504 | – | – | – | 7,297 | |||||||||||||||
| Split Dollar Life | 50,350 | 924 | – | 2,120 | 3,313 | |||||||||||||||
| 401(k) Matching Contribution | – | 3,450 | – | 3,450 | 3,450 | |||||||||||||||
| Group Health Insurance | 10,172 | 18,702 | 1,249 | 31,863 | 21,944 | |||||||||||||||
| Life/Disability Insurance | 407 | 482 | – | 449 | 482 | |||||||||||||||
| Netherlands Allowances | – | – | 12,346 | – | – | |||||||||||||||
| Total | 76,433 | 33,157 | 13,595 | 52,882 | 36,486 | |||||||||||||||
____________________
| (3) | $1,000,000 of the base salary and all of the cash bonus compensation paid to Dr. Berger in each year was paid by BRMG. | |
| (4) | Mr. Wesdorp became an employee and executive officer on October 1, 2024. Euros were converted into US dollars at a EUR to USD exchange rate of 1:1.04156 which was applied using the exchange rate in effect on December 31, 2024. |
Grants of Plan-Based Awards in 2024
The table below sets forth certain information with respect to grants of awards to our Named Executive Officers under the Equity Incentive Plan during 2024.
Estimated Future Payouts Under
Equity Incentive Plan Awards
| Name/Award Type | Grant Date | Threshold (#) | Target (#) | Maximum (#) | All Other Stock Awards; Number of Shares of Stock or Units (#) | All Other Option Awards: Number of Securities Underlying Options (#) | Exercise or Base Price of Option Awards ($/Sh) | Grant Date Fair Value of Stock and Option Awards ($) (3) | ||||||||||||||||||||||
| Howard G. Berger, M.D. | ||||||||||||||||||||||||||||||
| --Time-based RSUs (1) | 1.9.24 | – | – | – | 55,494 | – | – | 2,000,004 | ||||||||||||||||||||||
| Mark D. Stolper (2) | ||||||||||||||||||||||||||||||
| --Time-based RSUs (1) | 1.9.24 | – | – | – | 15,954 | – | – | 574,982 | ||||||||||||||||||||||
| Cornelis Wesdorp | ||||||||||||||||||||||||||||||
| --Time-based RS (1) | 10.1.24 | – | – | – | 50,000 | – | – | 3,410,500 | ||||||||||||||||||||||
| Vested Stock | 10.1.24 | – | – | – | 10,995 | – | – | 749,969 | ||||||||||||||||||||||
| Stephen M. Forthuber | ||||||||||||||||||||||||||||||
| --Time-based RS (1) | 1.9.24 | – | – | – | 18,036 | – | – | 650,017 | ||||||||||||||||||||||
| Norman R. Hames | ||||||||||||||||||||||||||||||
| --Time-based RSUs (1) | 1.9.24 | – | – | – | 18,036 | – | – | 650,017 | ||||||||||||||||||||||
_______________
| (1) | Subject to the Named Executive Officer’s continued service, the restricted shares/RSUs vest in three equal annual installments on March 10th of 2024, 2025 and 2026 (or, for Mr. Wesdorp, in five equal installments on October 1st of 2025, 2026, 2027, 2028, and 2029). The time-based vesting of unvested outstanding awards fully accelerates earlier upon: (a) a change in control of RadNet and (b) for those Named Executive Officers other than Mr. Wesdorp, termination of the Named Executive Officer’s service due to his death or Disability (as defined below) or termination of the Named Executive Officer’s service either by RadNet without Cause (as defined below) or by the Named Executive Officer for Good Reason (as defined below). |
| (2) | The equity award numbers listed above reflect the gross numbers granted and, for Mr. Stolper, include the portions of such awards that were transferred to Mr. Stolper’s former spouse pursuant to a domestic relations order. |
| (3) | For discussion regarding the valuation model and assumptions used to calculate the grant date fair value of these stock and option awards, see footnote (1) to the Summary Compensation Table. |
| 38 |
Outstanding Equity Awards at Fiscal Year End
The table below summarizes outstanding equity awards held by our Named Executive Officers at December 31, 2024. All of the below awards were issued under the Equity Incentive Plan.
| OPTION AWARDS | STOCK AWARDS | |||||||||||||||||||||||||||||||||
| Name | Number of Securities Underlying Unexercised Options(#) Exercisable (1) | Number of Securities Underlying Unexercised Options(#) Unexercisable (1) | Equity incentive plan awards: number of securities underlying unexercised unearned options (#) | Option Exercise Price($) | Option Expiration Date | Number of Shares or Units of Stock That Have Not Vested(#) | Market Value of Shares or Units of Stock That Have Not Vested($)(9) | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that have Not Vested (#) | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | |||||||||||||||||||||||||
| Howard G. Berger, M.D. | ||||||||||||||||||||||||||||||||||
| January 3, 2023 PSUs(5) | – | – | – | – | – | 40,236 | 2,810,082 | – | – | |||||||||||||||||||||||||
| January 3, 2023 PSO(5) | – | 77,976 | – | 18.64 | 1/3/33 | – | – | – | – | |||||||||||||||||||||||||
| January 3, 2023 Option | 69,312 | 34,657 | – | 18.64 | 1/3/33 | – | – | – | – | |||||||||||||||||||||||||
| January 9, 2024 RSUs(6) | – | – | – | – | 36,996 | 2,583,801 | – | – | ||||||||||||||||||||||||||
| Mark D. Stolper (7) | ||||||||||||||||||||||||||||||||||
| January 4, 2016 Option | 35,703 | – | – | 6.07 | 1/4/26 | – | – | – | – | |||||||||||||||||||||||||
| January 6, 2017 Option | 34,399 | – | – | 6.30 | 1/6/27 | – | – | – | – | |||||||||||||||||||||||||
| January 2, 2018 Option | 21,564 | – | – | 10.05 | 1/2/28 | – | – | – | – | |||||||||||||||||||||||||
| January 7, 2019 Option | 19,828 | – | – | 10.93 | 1/7/29 | – | – | – | – | |||||||||||||||||||||||||
| January 6, 2020 Option | 10,608 | – | – | 20.43 | 1/6/30 | – | – | – | – | |||||||||||||||||||||||||
| January 4, 2022 PSUs(4) | – | – | – | – | 1,113 | 77,732 | – | – | ||||||||||||||||||||||||||
| January 4, 2022 PSO(4) | 1,618 | 3,236 | – | 29.44 | 1/4/32 | – | – | – | – | |||||||||||||||||||||||||
| January 4, 2022 Option(2) | 20,681 | 5,909 | – | 29.44 | 1/4/32 | – | – | – | – | |||||||||||||||||||||||||
| January 4, 2022 Option (3) | 9,704 | – | – | 29.44 | 1/4/32 | – | – | – | – | |||||||||||||||||||||||||
| January 3, 2023 PSUs(5) | – | – | – | 14,072 | 982,788 | – | – | |||||||||||||||||||||||||||
| January 3, 2023 PSO(5) | – | 27,276 | – | 18.64 | 1/3/33 | – | – | – | – | |||||||||||||||||||||||||
| January 3, 2023 Option | 18,184 | 9,092 | – | 18.64 | 1/3/33 | – | – | – | – | |||||||||||||||||||||||||
| January 9, 2024 RSUs(6) | – | – | – | – | – | 9,705 | 677,797 | – | – | |||||||||||||||||||||||||
| Cornelis Wesdorp | ||||||||||||||||||||||||||||||||||
| October 1, 2024 RSUs(8) | – | – | – | – | – | 50,000 | 3,492,000 | – | – | |||||||||||||||||||||||||
| 39 |
| OPTION AWARDS | STOCK AWARDS | |||||||||||||||||||||||||||||||||
| Name | Number of Securities Underlying Unexercised Options(#) Exercisable (1) | Number of Securities Underlying Unexercised Options(#) Unexercisable (1) | Equity incentive plan awards: number of securities underlying unexercised unearned options (#) | Option Exercise Price($) | Option Expiration Date | Number of Shares or Units of Stock That Have Not Vested(#) | Market Value of Shares or Units of Stock That Have Not Vested($)(9) | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that have Not Vested (#) | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | |||||||||||||||||||||||||
| Stephen M. Forthuber | ||||||||||||||||||||||||||||||||||
| January 4, 2016 Option | 39,127 | – | – | 6.07 | 1/4/26 | – | – | – | – | |||||||||||||||||||||||||
| January 6, 2017 Option | 37,698 | – | – | 6.30 | 1/6/27 | – | – | – | – | |||||||||||||||||||||||||
| January 2, 2018 Option | 27,363 | – | – | 10.05 | 1/2/28 | – | – | – | – | |||||||||||||||||||||||||
| January 7, 2019 Option | 25,158 | – | – | 10.93 | 1/7/29 | – | – | – | – | |||||||||||||||||||||||||
| January 6, 2020 Option | 13,461 | – | – | 20.43 | 1/6/30 | – | – | – | – | |||||||||||||||||||||||||
| January 4, 2022 PSUs(4) | – | – | – | 1,380 | 96,379 | – | – | |||||||||||||||||||||||||||
| January 4, 2022 PSO(4) | 2,004 | 4,009 | – | 29.44 | 1/4/32 | – | – | – | – | |||||||||||||||||||||||||
| January 4, 2022 Option(2) | 25,900 | 7,400 | – | 29.44 | 1/4/32 | – | – | – | – | |||||||||||||||||||||||||
| January 4, 2022 Option (3) | 12,025 | – | – | 29.44 | 1/4/32 | – | – | – | – | |||||||||||||||||||||||||
| January 3, 2023 PSUs(5) | – | – | – | 17,434 | 1,217,591 | – | – | |||||||||||||||||||||||||||
| January 3, 2023 PSO(5) | – | 33,789 | – | 18.64 | 1/3/33 | – | – | – | – | |||||||||||||||||||||||||
| January 3, 2023 Option | 22,526 | 11,263 | – | 18.64 | 1/3/33 | – | – | – | – | |||||||||||||||||||||||||
| January 9, 2024 RS(6) | – | – | – | 12,024 | 839,756 | – | – | |||||||||||||||||||||||||||
| Norman R. Hames | ||||||||||||||||||||||||||||||||||
| January 2, 2018 Option | 11,194 | – | – | 10.05 | 1/2/28 | – | – | – | – | |||||||||||||||||||||||||
| January 7, 2019 Option | 8,386 | – | – | 10.93 | 1/7/29 | – | – | – | – | |||||||||||||||||||||||||
| January 6, 2020 Option | 13,461 | – | – | 20.43 | 1/6/30 | – | – | – | – | |||||||||||||||||||||||||
| January 4, 2022 PSUs(4) | – | – | – | 1,380 | $ | 96,379 | – | – | ||||||||||||||||||||||||||
| January 4, 2022 PSO(4) | 2,004 | 4,009 | – | 29.44 | 1/4/32 | – | – | – | – | |||||||||||||||||||||||||
| January 4, 2022 Option(2) | 25,900 | 7,400 | – | 29.44 | 1/4/32 | – | – | – | – | |||||||||||||||||||||||||
| January 4, 2022 Option (3) | 12,025 | – | – | 29.44 | 1/4/32 | – | – | – | – | |||||||||||||||||||||||||
| January 3, 2023 PSUs(5) | – | – | – | 17,434 | 1,217,591 | – | – | |||||||||||||||||||||||||||
| January 3, 2023 PSO(5) | – | 33,789 | – | 18.64 | 1/3/33 | – | – | – | – | |||||||||||||||||||||||||
| January 3, 2023 Option | 22,526 | 11,263 | – | 18.64 | 1/3/33 | – | – | – | – | |||||||||||||||||||||||||
| January 9, 2024 RSUs(6) | – | – | – | 12,024 | 839,756 | – | – | |||||||||||||||||||||||||||
| 40 |
____________________
| (1) | For options granted between 2016 and 2018, one-third of the options vest on the second anniversary of the date of grant and the remaining portion of the options vest in equal increments on the third and fourth anniversaries of the date of grant. For options granted in 2019 and 2020, one-third of the options incrementally vest on each of the first three anniversaries of the date of grant. |
| (2) | One-third of these stock options granted in 2022 vested on the date of grant. Subject to the Named Executive Officer’s continued service, the remaining two-thirds of these options vested in three equal annual installments on January 2nd of 2023, 2024 and 2025. The time-based vesting of unvested outstanding awards would fully accelerate earlier upon: (i) termination of the Named Executive Officer’s service due to his death or Disability or (ii) termination of the Named Executive Officer’s service either by RadNet without Cause or by the Named Executive Officer for Good Reason or (iii) a change in control of RadNet. |
| (3) | These stock options fully vested on January 4, 2023. |
| (4) | Performance equity compensation awards granted in 2022 have both time-based and performance-based vesting conditions. The performance vesting conditions were based on attainment of AEBITDA goals established by the Compensation Committee for calendar year 2022. The actual level of performance achievement was 95% of the target AEBITDA. The maximum number of shares subject to these PSOs had an aggregate grant date value approximately equal to the Black-Scholes option value of approximately 50% of the 2022 base salaries. The target number of shares subject to these PSUs have an aggregate grant date value approximately equal to 25% of the 2022 base salaries. The maximum number of PSUs that could vest was equal to 200% of the target number. The closing price of a common share on the grant date of January 4, 2022 was $29.44. The portion of the PSOs and PSUs that satisfied the AEBITDA performance vesting conditions (which figures are reflected in the above table) are also subject to continued service vesting conditions. 50% of those performance-vested PSUs incrementally vested on each of January 4th of 2024 and 2025. One-third of those performance-vested PSOs can incrementally vest on each of January 4th of 2024, 2025 and 2026. |
| (5) | Performance equity compensation awards granted in 2023 have both time-based and performance-based vesting conditions. The performance vesting conditions were based on attainment of AEBITDA goals established by the Compensation Committee for calendar year 2023. The actual level of performance achievement was 110.4% of the target AEBITDA. The maximum number of shares subject to these PSOs had an aggregate grant date value approximately equal to the Black-Scholes option value of approximately 50% of the 2022 base salaries. The target number of shares subject to these PSUs have an aggregate grant date value approximately equal to 25% of the 2022 base salaries. The maximum number of PSUs that could vest was equal to 200% of the target number. The closing price of a common share on the grant date of January 3, 2023 was $18.64. The portion of the PSOs and PSUs that satisfied the AEBITDA performance vesting conditions (which figures are reflected in the above table) are also subject to continued service vesting conditions. 50% of those performance-vested PSUs can incrementally vest on each of March 10th of 2025 and 2026. One-third of those performance-vested PSOs can incrementally vest on each of March 10th of 2025, 2026 and 2027. |
| (6) | For equity compensation awards granted in 2024, see footnotes (1) through (3) to the above Grants of Plan-Based Awards Table. The time-based vesting of unvested outstanding awards fully accelerates earlier than the above scheduled vesting upon: (a) termination of the Named Executive Officer’s service due to his death or Disability or (b) termination of the Named Executive Officer’s service either by RadNet without Cause or by the Named Executive Officer for Good Reason or (c) a change in control of RadNet. |
| (7) | The equity award numbers listed above are net of the portions transferred to Mr. Stolper’s former spouse pursuant to a domestic relations order. |
| (8) | Subject to Mr. Wesdorp’s continued service, the restricted shares vest in five equal annual installments on October 1st of 2025, 2026, 2027, 2028, and 2029. The then-outstanding unvested portion of this award becomes vested earlier upon a change in control of RadNet. |
| (9) | The aggregate market value is determined by multiplying the number of shares that have not vested by $69.84 per share, the last closing price of our common stock as of December 31, 2024. |
| 41 |
Option Exercises and Stock Vested During 2024
The following table sets forth information for the Named Executive Officers regarding the value realized during 2024 pursuant to the vesting of restricted stock, or “RSUs,” and exercised stock options.
| OPTION AWARDS | STOCK | AWARDS | ||||||||||||||
| Name | Number of Shares Acquired on Exercise (#) | Value Realized on Exercise ($) | Number of Shares Acquired on Vesting (#) | Value Realized on Vesting ($)(1) | ||||||||||||
| Howard G. Berger, M.D. | – | – | 45,322 | 2,107,926 | ||||||||||||
| Mark D. Stolper | – | – | 21,923 | 953,742 | ||||||||||||
| Cornelis Wesdorp | – | – | 10,995 | 749,969 | ||||||||||||
| Stephen M. Forthuber | – | – | 21,204 | 903,847 | ||||||||||||
| Norman R. Hames | – | – | 21,204 | 903,847 | ||||||||||||
_______________
| (1) | The value realized on vesting is equal to the product of the number of shares that became vested multiplied by the per share closing price of our common stock on the vesting date. The below table shows the details of the figures reported in the above table. The figures shown for Mr. Stolper are net of the portions of his equity compensation awards that were transferred to his former spouse pursuant to a domestic relations order. |
| Name | Grant Date | Vesting Date | Closing Share Price on Vesting Date ($) | Number of Shares Vesting (#) | Value Realized on Vesting Date ($) | |||||||||||
| Howard G. Berger, M.D. | 1/3/23 | 3/10/24 | 46.51 | 26,824 | 1,247,584 | |||||||||||
| 1/9/24 | 3/10/24 | 46.51 | 18,498 | 860,342 | ||||||||||||
| Mark D. Stolper | 1/4/22 | 1/3/24 | 33.57 | 4,068 | 136,563 | |||||||||||
| 1/4/22 | 1/4/24 | 34.61 | 1,114 | 38,556 | ||||||||||||
| 1/3/23 | 3/10/24 | 46.51 | 7,036 | 327,244 | ||||||||||||
| 1/9/24 | 3/10/24 | 46.51 | 9,705 | 461,380 | ||||||||||||
| Cornelis Wesdorp | 10/1/24 | 10/1/24 | 68.21 | 10,995 | 749,969 | |||||||||||
| Stephen M. Forthuber | 1/4/22 | 1/3/24 | 33.57 | 5,095 | 171,039 | |||||||||||
| 1/4/22 | 1/4/24 | 34.61 | 1,380 | 47,762 | ||||||||||||
| 1/3/23 | 3/10/24 | 46.51 | 8,717 | 405,428 | ||||||||||||
| 1/9/24 | 3/10/24 | 46.51 | 6,012 | 279,618 | ||||||||||||
| Norman R. Hames | 1/4/22 | 1/3/24 | 33.57 | 5,095 | 171,039 | |||||||||||
| 1/4/22 | 1/4/24 | 34.61 | 1,380 | 47,762 | ||||||||||||
| 1/3/23 | 3/10/24 | 46.51 | 8,717 | 405,428 | ||||||||||||
| 1/9/24 | 3/10/24 | 46.51 | 6,012 | 279,618 | ||||||||||||
| 42 |
Pension Benefits and Nonqualified Deferred Compensation Plans
We do not have any tax-qualified defined benefit plans or supplemental executive retirement plans that provide for payments or other benefits to our Named Executive Officers in connection with their retirement. However, we do maintain the Deferred Compensation Plans.
The employment arrangements of the below Named Executive Officers include a required payment of deferred compensation upon termination of employment in certain situations. The following table shows the contributions, earnings and distributions of nonqualified deferred compensation during the fiscal year ended December 31, 2024.
Nonqualified Deferred Compensation
| Name | Executive Contributions in Last Fiscal Year ($) | Registrant Contributions in Last Fiscal Year ($) | Aggregate Earnings in Last Fiscal Year ($)(4) | Aggregate Withdrawals/ Distributions ($) | Aggregate Balance at Last Fiscal Year End ($)(5) | |||||||||||||||
| Howard G. Berger, M.D. (1) | 2,000,004 | – | 5,168,209 | – | 12,932,560 | |||||||||||||||
| Mark D. Stolper (2) | 524,670 | – | 5,933,346 | – | 11,852,755 | |||||||||||||||
| Norman R. Hames (3) | 1,170,017 | – | 2,319,710 | – | 7,500,979 | |||||||||||||||
_______________
| (1) | In 2024, Dr. Berger elected to defer receipt of his 2024 stock grants, resulting in his receipt of 55,494 RSUs from a grant issued on January 9, 2024. On the date of grant of these RSUs, the Company share price was $36.04. On December 31, 2024 the Company share price was $69.84. For Dr. Berger, $2,000,004 has been reported as compensation in the Summary Compensation Table for 2024. Pursuant to the Management Consulting Agreement dated as of January 1, 1994, as amended, between Dr. Berger and BRMG, upon Dr. Berger’s resignation or RadNet’s termination of his employment without cause by the Company, Dr. Berger is entitled to receive an amount equal to five times his 2010 base salary paid by BRMG (and $2,500,000 is included in the Aggregate Balance column). Upon termination of his employment by the Company for cause, Dr. Berger is entitled to an amount equal to his 2010 base salary paid by BRMG. Dr. Berger’s 2010 base salary as paid by BRMG was $500,000. Such post-employment payment is subject to post-termination covenants intended to protect RadNet’s business. As of December 31, 2024, Dr. Berger was holding a total of 149,378 RSUs/PSUs. |
| (2) | In 2024, Mr. Stolper elected to defer receipt of his 2024 stock grants (net of shares transferred to his former spouse pursuant to a domestic relations order), resulting in his receipt of 14,558 RSUs from a grant issued on January 9, 2024. On the date of grant of these RSUs, the Company share price was $36.04. On December 31, 2024 the Company share price was $69.84. For Mr. Stolper, $574,982 has been reported as compensation in the Summary Compensation Table for 2024, which represents the value of this RSU grant prior to the transfer of shares to his former spouse in accordance with a domestic relations order. As of December 31, 2024, Mr. Stolper was holding a total of 169,713 RSUs/PSUs. |
| (3) | In 2024, Mr. Hames elected to defer receipt of his 2024 stock grants, resulting in his receipt of 18,036 RSUs from a grant issued on January 8, 2024. On the date of grant of these RSUs, the Company share price was $36.04. On December 31, 2024 the Company share price was $69.84. Pursuant to the Employment Agreement dated as of September 1, 2022, upon Mr. Hames’ resignation or RadNet’s termination of employment without cause, Mr. Hames is entitled to receive an amount equal to three times his 2010 base salary (and $1,050,000 is included the Aggregate Balance column). Upon termination of his employment by the Company for cause, Mr. Hames is entitled to an amount equal to his 2010 base salary. Mr. Hames’ 2010 base salary was $350,000. Such post-employment payment is subject to post-termination covenants intended to protect RadNet’s business. In 2024, Mr. Hames contributed $520,000 of a bonus payment into the Excess Plan and his Excess Plan account increased by $487,237 due to notional investment performance. Mr. Hames’ balance under the Excess Plan as of December 31, 2024 was $2,756,094. For Mr. Hames, $1,170,017 has been reported as compensation in the Summary Compensation Table for 2024. As of December 31, 2024, Mr. Hames was holding a total of 52,905 RSUs/PSUs. |
| (4) | Amount represents stock price appreciation in 2024 on all RSUs/PSUs and gains on notional investments made under the Excess Plan. No portion of any such appreciation or depreciation has been reported as compensation in the Summary Compensation Table for 2024. The below table provides the details on the aggregate earnings for each of the below named executive officers in 2024. |
| 43 |
| Name | Outstanding RSUs as of 12.31.23 | New RSUs in 2024 | 2024 Share Price Change | Excess Plan Earnings | Total | |||||||||||||||
| Dr. Berger | 93,884 | – | $ | 35.07 | – | $ | 3,292,512 | |||||||||||||
| – | 55,494 | $ | 33.80 | – | 1,875,697 | |||||||||||||||
| $ | 5,168,209 | |||||||||||||||||||
| Mr. Stolper | 155,155 | – | $ | 35.07 | – | $ | 5,441,286 | |||||||||||||
| – | 14,558 | $ | 33.80 | – | 492,060 | |||||||||||||||
| $ | 5,933,346 | |||||||||||||||||||
| Mr. Hames | 34,869 | – | $ | 35.07 | – | $ | 1,222,856 | |||||||||||||
| – | 18,036 | $ | 33.80 | – | 609,617 | |||||||||||||||
| – | – | – | $ | 487,237 | 487,237 | |||||||||||||||
| $ | 2,319,710 | |||||||||||||||||||
| (5) | Of the $12,932,560 reported for Dr. Berger, $2,000,004 is reported in the Summary Compensation Table for 2024 and a total of $1,375,000 was reported for Dr. Berger in the Summary Compensation Table for prior years. Of the $11,852,755 reported for Mr. Stolper, $574,982 is reported in the Summary Compensation Table for 2024 and a total of $2,006,793 was reported for Mr. Stolper in the Summary Compensation Table for prior years. Of the $6,450,979 reported for Mr. Hames, $1,170,017 is reported in the Summary Compensation Table for 2024 and a total of $2,087,115 was reported for Mr. Hames in the Summary Compensation Table for prior years. |
Employment Agreements
On September 1, 2022, RMI entered into new executive employment agreements (each an “Agreement” and together the “Agreements”) with our Named Executive Officers other than Mr. Wesdorp (whose employment agreement is described further below) and Dr. Berger (whose Agreement with RMI was executed on April 20, 2023), pursuant to which each such Named Executive Officer will continue to be employed by RMI under the terms and conditions of the Agreements. Under the Agreements, employment is “at will” and may be terminated by either RMI or the Named Executive Officer at any time. The Agreements generally have uniform terms and conditions and they replace and supersede all existing employment agreements although certain individual-specific legacy provisions from the former agreements are retained in the Agreements.
Under the Agreements, each Named Executive Officer is eligible to:
(a) receive an annual base salary (subject to adjustment in the discretion of our Board of Directors or its compensation committee);
(b) participate in bonus and incentive compensation plans (Dr. Berger’s bonuses are paid by BRMG);
(c) receive full vesting of the time-based vesting portions of their outstanding equity compensation awards upon a “change in control” of the Company (which term is defined in the Equity Incentive Plan);
(d) receive reimbursement for all reasonable business expenses and be covered under directors and officers liability insurance coverage;
(e) receive six weeks annual paid vacation in accordance with RMI’s vacation policy for employees and receive medical, disability and life insurance coverage and such sick leave and holiday benefits, if any, and any other benefits as are made available to executive officers generally; and
(f) receive transportation assistance in the form of either a RMI provided automobile or in the form of a monthly automobile allowance.
| 44 |
Upon termination of employment for any reason RMI shall pay or provide to the Named Executive Officer, or the Named Executive Officer’s estate, the annual base salary, prorated through the date of termination. Unless his employment is terminated due to his death or disability, Mr. Hames will (on his termination date) also receive a lump sum payment of $1,050,000 (the “Hames Termination Payment”) (or $350,000 if his employment was terminated for Cause (as defined in his Agreement)).
In the event that the Named Executive Officer’s employment by RMI is terminated due to the Named Executive Officer’s death, then:
(a)the Named Executive Officer’s representative shall have up until the first anniversary of the termination of employment (or the applicable expiration date if earlier) to exercise the Named Executive Officer’s vested stock options; and
(b)the Named Executive Officer shall receive full vesting of the time-based vesting portions of the Named Executive Officer’s outstanding equity compensation awards.
In the event that the Named Executive Officer’s employment by RMI is terminated due to the Named Executive Officer’s Disability, then:
(a)the Named Executive Officer shall receive the same benefits provided above in the case of the Named Executive Officer’s death; and
(b)the Named Executive Officer shall receive a lump sum payment (within 15 days after the effectiveness of the required release of claims) in an amount equal to the sum of the Named Executive Officer’s then annual base salary plus the greater of the Named Executive Officer’s prior year annual cash bonus or the average of the Named Executive Officer’s prior three years annual cash bonus (the greater of such two bonuses is the “Severance Bonus”).
In the event that the Named Executive Officer’s employment by RMI is terminated either by RMI without Cause, or by the Named Executive Officer for Good Reason (either a “Qualifying Termination”), then:
(a)the Named Executive Officer shall receive severance in an amount equal to the Severance Pay (defined below);
(b)the Named Executive Officer shall receive full vesting of the time-based vesting portions of the Named Executive Officer’s outstanding equity compensation awards; and
(c)RMI shall (l) pay the cost of the premium for the Named Executive Officer to receive continuation coverage (as defined in the Consolidation Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”)) under RMI’s (or the Company’s) group medical plan until the earlier of (i) the second anniversary of the termination date or (ii) the maximum time for which COBRA continuation coverage is permitted under applicable law or (iii) the date on which the Named Executive Officer obtains substantially equivalent benefits from another party and (2) continue to provide the Named Executive Officer with life insurance coverage in accordance with RMI’s (or the Company’s) benefits program until the earlier of (i) the second anniversary of the termination date or (ii) the date on which the Named Executive Officer obtains substantially equivalent benefits from another party. If the Named Executive Officer was not then covered under the applicable benefit plan at the time of termination then RMI shall pay the Named Executive Officer the cash equivalent for such benefit.
For purposes of the above, “Severance Pay” means a dollar amount that is equal to: (a) if the number of the Named Executive Officer’s years of service with RMI is less than five, the Named Executive Officer’s then annual base salary, (b) if the number of the Named Executive Officer’s years of service with RMI is at least five but less than ten, the sum of the Named Executive Officer’s then annual base salary plus the Severance Bonus, or (c) if the number of the Named Executive Officer’s years of service with RMI is at least ten, the sum of 200% of the Named Executive Officer’s then annual base salary plus 200% of the Severance Bonus. In the case of Dr. Berger, Severance Pay would be reduced by $2,500,000 (which is an amount he would be paid under his Management Consulting Agreement with BRMG). In the case of Mr. Hames, Severance Pay would be reduced by the Hames Termination Payment. All of the Named Executive Officers presently have accumulated more than ten years of service with RMI. The Severance Pay would generally be paid out in equal installments over the twenty-four months after termination except that for Mr. Forthuber it would be paid in a single lump sum within 15 days after the effectiveness of the required release of claims if the termination occurred within one year after a change in control and Mr. Stolper it would be paid in a single lump sum within 15 days after the effectiveness of the required release of claims.
| 45 |
In order to receive any of the above post termination compensation and benefits for a Qualifying Termination or termination due to death or disability, the Named Executive Officer or his representative must timely sign and not revoke a complete and general release of claims in a form to be reasonably determined by RMI.
Below are summaries of certain definitions contained in the Agreements.
“Cause” shall generally mean any one or more of the following:
(i)the Named Executive Officer’s conviction of (or plea of guilty or nolo contendere to) (A) any felony or (B) any misdemeanor involving fraud or dishonesty in connection with the performance of his duties hereunder or moral turpitude;
(ii)the willful and continued failure of the Named Executive Officer to substantially perform his duties with RMI (other than any such failure resulting from illness or Disability) after a written demand for substantial performance from the Named Executive Officer is delivered to the Named Executive Officer, which demand identifies the manner in which it is claimed the Named Executive Officer has not substantially performed his duties;
(iii)the Named Executive Officer has willfully engaged in misconduct which has, or can reasonably be expected to have, a material adverse effect on the Group; or
(iv)the Named Executive Officer material breach of the Agreement or any other written agreement with the Group.
No act or failure to act on the Named Executive Officer’s part shall be considered “willful” unless the Named Executive Officer acted in bad faith or without a reasonable belief that the Named Executive Officer’s action or omission was in the best interest of the Group.
Solely to the extent that our Board of Directors determines in its reasonable discretion that the Cause conduct is curable, the Named Executive Officer shall have ten (10) business days after receipt of notice that the Group believes it has grounds to terminate the Named Executive Officer’s employment for Cause to entirely cure the Cause conduct under subsections (ii) through (iv) above and its consequences to the satisfaction of our Board of Directors and thereby avoid termination of the Named Executive Officer’s employment for Cause if so determined by our Board of Directors in its sole discretion. During any time period when the Group believes that (or is in the process of investigating whether) the Named Executive Officer may have committed an act of Cause (or has committed an act which could result in constituting Cause under any of the above subsection), RMI may in its discretion place the Named Executive Officer on a leave of absence and/or preclude the Named Executive Officer from utilizing Group resources or having access to Group premises. If after the Named Executive Officer’s termination date which occurred due to a reason other than termination by RMI for Cause, the Group discovers that the Named Executive Officer’s employment could have been terminated for Cause, then the Group may in its discretion recharacterize such termination as a termination for Cause.
“Disability” generally means that for a period of at least 120 days during any twelve (12) consecutive month period on account of a mental or physical condition, the Named Executive Officer is unable to perform the essential functions of his job for RMI, with or without reasonable accommodation. The determination of the Named Executive Officer’s Disability shall be made by a medical physician selected or agreed to by the Group unless there is mutual agreement of RMI and the Named Executive Officer or his personal representative.
“Group” means the Company and its affiliated entities.
“Good Reason” generally means any one or more of the following have occurred without the Named Executive Officer’s prior written consent:
(i)RMI’s material breach of the Agreement or any other written agreement between the Company and the Named Executive Officer; or
(ii)an Adverse Change in Duties.
| 46 |
For purposes of the above clause (ii), “Adverse Change in Duties” generally means an action or series of actions taken by RMI and/or its board of directors or the Company Board of Directors, without the Named Executive Officer’s prior written consent, which results in any one or more of the following:
(i)a change in the Named Executive Officer’s reporting structure, positions, titles, job duties or job functions which results in a material diminution of his status, control, authority or level of responsibility;
(ii)a requirement by RMI that Employee be based or perform his duties more than ten miles away from his primary work location;
(iii)a reduction by RMI in the Named Executive Officer’s base compensation; or
(iv)for each of the first two complete fiscal years immediately following the fiscal year in which a change in control of RadNet occurs, the Named Executive Officer’s post change in control annual incentive compensation is less than a calculated annual incentive compensation threshold. This threshold is the lesser of $1 million or 50% of a specified pre change in control annual paid incentive compensation amount.
In order for the Named Executive Officer to resign his employment for Good Reason, the Named Executive Officer must provide written notice to the Company within ninety (90) days of the initial existence of the alleged Good Reason event and such notice must reasonably describe the facts claimed by the Named Executive Officer to constitute Good Reason and the alleged Good Reason event remains unremedied by the Company for a period of sixty (60) days following the Company’s receipt of such written notice and the Named Executive Officer must resign his employment for Good Reason within sixty (60) business days after the expiration of the Company’s sixty (60) day remedy period in which the Company did not cure or remedy the Good Reason event.
The Agreements also contain provisions regarding, among other things, confidential information, governing law, dispute resolutions and covenants governing the Named Executive Officer’s conduct.
The Agreements were each amended as of January 1, 2024 solely to reflect adjustments to annual base salary. All other terms of the Agreements remained unchanged.
Dr. Berger Management Consulting Agreement. Dr. Berger has a Management Consulting Agreement with BRMG dated January 1, 1994. Under the terms of the Management Consulting Agreement, in the event of termination (other than due to death or disability) or voluntary resignation “without cause,” upon his termination date Dr. Berger is entitled to receive a severance payment in an amount equal to five times his 2010 BRMG annual compensation, or $2,500,000, such amount also payable in certain other circumstances as set forth under the “Nonqualified Deferred Compensation” section above. Separately, in the event of termination “for cause” by BRMG, Dr. Berger is entitled to receive compensation in an amount equal to his 20l0 annual base compensation from an affiliate of BRMG, or $500,000. BRMG may terminate Dr. Berger’s consulting services “for cause” if (1) there is a material breach by Dr. Berger of the agreement which persists for more than thirty (30) days after notice of such breach has been provided, (2) Dr. Berger willfully breaches or habitually neglects his duties, (3) Dr. Berger commits any acts of a criminal nature, fraud, dishonest misrepresentations or any acts of moral turpitude, (4) Dr. Berger’s professional license is suspended, revoked or terminated or (5) Dr. Berger is convicted of a felony or of fraud involving payments or charges for professional medical services.
Cornelis Wesdorp Employment Agreement. On September 11, 2024, Mr. Wesdorp entered into an employment agreement (the “Wesdorp Employment Agreement”) with Aidence B.V., a wholly owned subsidiary of RadNet, which provides that he will serve as a director of Aidence B.V. and as President and Chief Executive Officer of the RadNet Digital Health Division. Mr. Wesdorp will be based in the Netherlands. The employment term started October 1, 2024, and will continue until terminated by either Aidence B.V. or Mr. Wesdorp. Any such termination can be effected by giving written notice to the other party and with due observance of the respective statutory notice periods.
| 47 |
Under the Wesdorp Employment Agreement, Mr. Wesdorp will receive (a) an annual base salary of €636,000, (b) reimbursement for a family medical insurance premium, (c) five weeks (twenty-five days) of vacation per year, and (d) reimbursement of all reasonably incurred business expenses. Mr. Wesdorp will also receive a bonus equal to his annual compensation in both 2026 and 2027, payable on the date that RadNet pays bonuses to its executive officers for that year, provided that (i) the Wesdorp Employment Agreement remains in effect on such payment date and (ii) Mr. Wesdorp has not been sick or incapacitated for more than an aggregate of thirty calendar days during the twelve months immediately preceding such payment date.
In connection with Mr. Wesdorp’s commencement of employment, RadNet agreed to provide Mr. Wesdorp with a signing bonus of $750,000 payable in shares of RadNet common stock (valued on the commencement of employment) and to grant Mr. Wesdorp restricted stock units for 50,000 shares of RadNet common stock, which will vest in equal 10,000 share increments on each of the succeeding five anniversaries of the commencement of employment, subject to Mr. Wesdorp’s continued service. These equity compensation awards were issued under RadNet’s Equity Incentive Plan.
The Wesdorp Employment Agreement contains commercially standard covenants regarding the protection of confidential information and intellectual property rights, as well as restrictions against Mr. Wesdorp competing against RadNet or soliciting its employees during the term of the agreement and for a period of twelve months following its termination. The Wesdorp Employment Agreement also contains provisions regarding, among other things, governing law, dispute resolutions and covenants governing Mr. Wesdorp’s conduct.
Potential Payments Upon Termination or Change in Control
Payments Made Upon Termination
Regardless of the manner in which the employment of a Named Executive Officer is terminated, he is entitled to receive vested amounts that were earned during his term of employment. Such amounts include:
non-equity incentive compensation earned, to the extent vested;
equity awarded pursuant to our Equity Incentive Plan, to the extent vested, including without limitation amounts accrued under the Deferred Compensation Plans; and
unused vacation pay.
The foregoing items will be provided in connection with any termination of employment. In addition, except if termination of employment was due to death, Dr. Berger and Mr. Hames will also receive certain termination payments specified above in the Employment Agreements section.
Payments Made Upon Death or Disability
In the event of the death of a Named Executive Officer (other than Mr. Wesdorp) resulting in termination of employment, the Named Executive Officer’s beneficiaries will receive life insurance proceeds: (a) the COLI policy death benefit proceeds payable would be $5 million for Dr. Berger and $1 million for each of the other Named Executive Officers and (b) the group life insurance plans death benefit proceeds payable would be $20,000 for Dr. Berger and $100,000 for each of the other Named Executive Officers. In the event of the Disability of a Named Executive Officer (other than the Chief Executive Officer or Mr. Wesdorp) resulting in termination of employment the Named Executive Officer shall receive a lump sum payment in an amount equal to the sum of the Named Executive Officer’s then annual base salary plus the greater of the Named Executive Officer’s prior year annual cash bonus or the average of the Named Executive Officer’s prior three years annual cash bonus. In the event of either the death or Disability of a Named Executive Officer resulting in termination of employment, the time vesting portions of all of the Named Executive Officer’s outstanding unvested equity compensation awards will become vested.
| 48 |
Severance and Change in Control Arrangements
Pursuant to our employment agreements with our Named Executive Officers (other than Mr. Wesdorp), we have severance obligations to the Named Executive Officers upon certain terminations of employment as discussed above under the heading “Employment Agreements.” Additionally, their employment agreements provide for full vesting of time-based vesting conditions of outstanding equity compensation awards upon a change in control.
Quantitative Estimates
The following table provides numerical estimates of potential payments upon termination of service or a change in control and assumes:
The applicable triggering event occurred on December 31, 2024.
The price per share used to calculate the value of equity compensation awards was $69.84 which was our last closing price per share as of December 31, 2024 which was the last trading day for fiscal year 2024.
The value of a share underlying equity compensation awards is assumed to be the difference between $69.84 minus any applicable purchase or exercise price.
All unvested equity compensation awards are assumed to become vested upon a (a) Qualifying Termination (other than for Mr. Wesdorp) or (b) change in control with performance awards vesting at their maximum levels.
For the Named Executive Officers, the unused vacation pay has been estimated using the maximum permitted accrual amount for each Named Executive Officer under the applicable vacation policy. These maximum limits are as follows: Dr. Berger – 160 hours; Messrs. Stolper and Hames – 320 hours each; Mr. Forthuber – 400 hours; Mr. Wesdorp – 200 hours.
The estimated premium for each Named Executive Officer (other than Mr. Wesdorp) to receive (a) COBRA continuation coverage under RMI’s (or the Company’s) group medical plan until the second anniversary of the officer’s termination date and (b) continued life insurance coverage in accordance with RMI’s (or the Company’s) benefits program until the second anniversary of the officer’s termination date are provided in the below table:
| Name | COBRA Continuation($) | Life Insurance($) | ||||||
| Howard G. Berger, M.D. | 13,794 | 100,700 | ||||||
| Mark D. Stolper | 25,371 | 1,847 | ||||||
| Stephen M. Forthuber | 43,225 | 4,240 | ||||||
| Norman R. Hames | 29,770 | 6,626 | ||||||
The below dollar amounts are estimates only for a particular point in time and do not necessarily reflect the actual amounts that would be paid to a Named Executive Officer upon a triggering event. For Mr. Wesdorp, in calculating his vacation payout, his annual base salary, which is paid in Euros, was converted into US dollars at a EUR to USD exchange rate of 1:1.04156 which was applied using the exchange rate in effect on December 31, 2024. For Dr. Berger, the amounts below include the post-termination payments provided by BRMG as described above in the Dr. Berger Management Consulting Agreement section.
| 49 |
Resignation ($) | Termination for Cause ($) | Termination due to Death ($) | Termination Due to Disability ($) | Resignation for Good Reason or Termination without Cause ($) | Change in Control ($) | |||||||||||||||||||
| Howard G. Berger, M.D. | ||||||||||||||||||||||||
| Cash Separation Payments | $ | 2,500,000 | $ | 500,000 | $ | 5,020,000 | $ | – | $ | 14,000,000 | $ | – | ||||||||||||
| Excess Plan Deferred Compensation | – | – | – | – | – | – | ||||||||||||||||||
| Continuation of Health/Life Insurance Benefits | – | – | – | – | 114,494 | – | ||||||||||||||||||
| Accrued Unused Vacation | 346,154 | 346,154 | 346,154 | 346,154 | 346,154 | – | ||||||||||||||||||
| Previously Vested RSU/Option Awards | 8,587,451 | 5,038,677 | 8,587,451 | 8,587,451 | 8,587,451 | 8,587,451 | ||||||||||||||||||
| Acceleration of Vesting of Unvested Equity Compensation Awards | – | – | 11,160,692 | 11,160,692 | 11,160,692 | 11,160,692 | ||||||||||||||||||
| Total | $ | 11,433,605 | $ | 5,884,830 | $ | 25,114,297 | $ | 20,094,297 | $ | 34,208,791 | $ | 19,748,144 | ||||||||||||
Resignation ($) | Termination for Cause ($) | Termination due to Death ($) | Termination Due to Disability ($) | Resignation for Good Reason or Termination without Cause ($) | Change in Control ($) | |||||||||||||||||||
| Mark D. Stolper | ||||||||||||||||||||||||
| Cash Separation Payments | $ | – | $ | – | $ | 1,100,000 | $ | 1,275,000 | $ | 2,550,000 | $ | – | ||||||||||||
| Excess Plan Deferred Compensation | – | – | – | – | – | – | ||||||||||||||||||
| Continuation of Health/Life Insurance Benefits | – | – | – | – | 27,218 | – | ||||||||||||||||||
| Accrued Unused Vacation | 107,692 | 107,692 | 107,692 | 107,692 | 107,692 | – | ||||||||||||||||||
| Previously Vested RSU/Option Awards | 19,782,393 | 10,114,438 | 19,782,393 | 19,782,393 | 19,782,393 | 19,782,393 | ||||||||||||||||||
| Acceleration of Vesting of Unvested Equity Compensation Awards | – | – | 3,969,817 | 3,969,817 | 3,969,817 | 3,969,817 | ||||||||||||||||||
| Total | $ | 19,890,086 | $ | 10,222,131 | $ | 24,959,903 | $ | 25,134,903 | $ | 26,437,121 | $ | 23,752,211 | ||||||||||||
Resignation ($) | Termination for Cause ($) | Termination due to Death ($) | Termination Due to Disability ($) | Resignation for Good Reason or Termination without Cause ($) | Change in Control ($) | |||||||||||||||||||
| Cornelis Wesdorp | ||||||||||||||||||||||||
| Cash Separation Payments | $ | – | $ | – | $ | – | $ | – | $ | – | $ | – | ||||||||||||
| Excess Plan Deferred Compensation | – | – | – | – | – | – | ||||||||||||||||||
| Continuation of Health/Life Insurance Benefits | – | – | – | – | – | – | ||||||||||||||||||
| Accrued Unused Vacation | 63,695 | 63,695 | 63,695 | 63,695 | 63,695 | – | ||||||||||||||||||
| Previously Vested RSU/Option Awards | – | – | – | – | – | – | ||||||||||||||||||
| Acceleration of Vesting of Unvested Equity Compensation Awards | – | – | – | – | – | 3,492,000 | ||||||||||||||||||
| Total | $ | 63,695 | $ | 63,695 | $ | 63,695 | $ | 63,695 | $ | 63,695 | $ | 3,492,000 | ||||||||||||
| 50 |
Resignation ($) | Termination for Cause ($) | Termination due to Death ($) | Termination Due to Disability ($) | Resignation for Good Reason or Termination without Cause ($) | Change in Control ($) | |||||||||||||||||||
| Stephen M. Forthuber | ||||||||||||||||||||||||
| Cash Separation Payments | $ | – | $ | – | $ | 1,100,000 | $ | 1,250,000 | $ | 2,900,000 | $ | – | ||||||||||||
| Excess Plan Deferred Compensation | – | – | – | – | – | – | ||||||||||||||||||
| Continuation of Health/Life Insurance Benefits | – | – | – | – | 47,465 | – | ||||||||||||||||||
| Accrued Unused Vacation | 153,846 | 153,846 | 153,846 | 153,846 | 153,846 | – | ||||||||||||||||||
| Previously Vested RSU/Option Awards | 11,440,122 | – | 11,440,122 | 11,440,122 | 11,440,122 | 11,440,122 | ||||||||||||||||||
| Acceleration of Vesting of Unvested Equity Compensation Awards | – | – | 4,921,312 | 4,921,312 | 4,921,312 | 4,921,312 | ||||||||||||||||||
| Total | $ | 11,593,968 | $ | 153,846 | $ | 17,615,280 | $ | 17,965,280 | $ | 19,462,745 | $ | 16,361,434 | ||||||||||||
Resignation ($) | Termination for Cause ($) | Termination due to Death ($) | Termination Due to Disability ($) | Resignation for Good Reason or Termination without Cause ($) | Change in Control ($) | |||||||||||||||||||
| Norman R. Hames | ||||||||||||||||||||||||
| Cash Separation Payments | $ | 1,050,000 | $ | 350,000 | $ | 1,100,000 | $ | 1,450,000 | $ | 2,900,000 | $ | – | ||||||||||||
| Excess Plan Deferred Compensation | 2,756,094 | 2,756,094 | 2,756,094 | 2,756,094 | 2,756,094 | 2,756,094 | ||||||||||||||||||
| Continuation of Health/Life Insurance Benefits | – | – | – | – | 36,396 | – | ||||||||||||||||||
| Accrued Unused Vacation | 123,077 | 123,077 | 123,077 | 123,077 | 123,077 | – | ||||||||||||||||||
| Previously Vested RSU/Option Awards | 6,136,039 | 1,541,159 | 6,136,039 | 6,136,039 | 6,136,039 | 6,136,039 | ||||||||||||||||||
| Acceleration of Vesting of Unvested Equity Compensation Awards | – | – | 4,921,312 | 4,921,312 | 4,921,312 | 4,921,312 | ||||||||||||||||||
| Total | $ | 10,065,210 | $ | 4,770,330 | $ | 15,036,521 | $ | 15,396,521 | $ | 16,872,917 | $ | 13,813,445 | ||||||||||||
Pay Ratio Disclosure
Under SEC rules we are required to disclose the ratio of our median employee’s total annual compensation to the total annual compensation of Dr. Berger, our principal executive officer.
In determining the median employee, we prepared a list of all employees as of December 31, 2024. We excluded 159 employees based in our international locations (Canada-28, the Netherlands-77, India-26, the United Kingdom-19, Germany-3, Romania-1, Spain-1, Bulgaria-1, Finland-1 and Portugal-2) because they represented less than 2% of our total employees and their exclusion did not have a material effect on the median calculation. We do not grant equity compensation awards widely to our employees, and consequently determined that annual gross wages is an appropriate compensation metric to utilize. We selected our median employee based on the annual gross wages reflected in our payroll records in 2024, which includes part-time, temporary and international employees (we do not have any seasonal employees).
| 51 |
For 2024, the pay ratio calculation is as follows, showing that for 2024, the PEO’s total annual compensation was 208 times that of the median of the total annual compensation of all employees other than the PEO:
| Median Employee Annual Total Compensation | $43,611 |
| Dr. Berger (“PEO”) Annual Total Compensation | $9,076,437 |
| Ratio of PEO to Median Employee Compensation | 208 |
Because the SEC rules for identifying the median employee and calculating the pay ratio based on that employee’s total annual compensation allow companies to use a variety of methodologies, to apply certain exclusions and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices, the pay ratio reported by other companies may not be comparable to our pay ratio, as other companies may utilize different methodologies, exclusions, estimates and assumptions in calculating their pay ratios. These companies may also operate in different industries and different geographic locations, be of a different size, have different revenues, earnings and market capitalization and be subject to different regulations than RadNet.
Pay Versus Performance
As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive compensation actually paid and certain financial performance of the Company. The disclosures included in this section are prescribed by SEC rules and do not necessarily align with how the Company, our Board, or the Compensation Committee view the link between the Company’s performance and Named Executive Officer pay, and neither the Board nor the Compensation Committee uses compensation actually paid as the basis for making compensation decisions. The tabular disclosure and the following graphs were calculated in accordance with SEC rules and do not fully represent the actual final amount of compensation earned by or actually paid to our Named Executive Officers during the applicable fiscal years. For further information concerning the Company’s pay-for-performance philosophy and how the Company’s aligns executive compensation with the Company’s performance, refer to the above Compensation Discussion and Analysis section.
Pay Versus Performance
| Value of Initial Fixed $100 Investment Based On: | |||||||||||||||||||||||||||||||||
| Year | Summary Compensation Table Total for PEO1 | Compensation Actually Paid to PEO2 | Average Summary Compensation Table Total for Non-PEO Named Executive Officers3 | Average Compensation Actually Paid to Non-PEO Named Executive Officers4 | Total Shareholder Return5 | Peer Group Total Shareholder Return6 | Net Income (millions)7 | Adjusted EBITDA (millions)8 | |||||||||||||||||||||||||
| (a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | |||||||||||||||||||||||||
| 2024 | $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||
| 2023 | $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||
| 2022 | $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||
| 2021 | $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||
| 2020 | $ | $ | $ | $ | $ | $ | ($ | ) | $ | ||||||||||||||||||||||||
_______________
(1) | The dollar amounts reported in column (b) are the amounts of total
compensation reported for | |
| (2) | The dollar amounts reported in column (c) represent the amount of “compensation actually paid” to Dr. Berger, as computed in accordance with Item 402(v) of Regulation S-K. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Dr. Berger’s total compensation for 2023 to determine the compensation actually paid: |
| 52 |
| Year | Reported Summary Compensation Table Total for PEO | Reported Value of Equity Awards | Equity Award Adjustments(a) | Reported Change in the Actuarial Present Value of Pension Benefits(b) | Pension Benefit Adjustments(c) | Compensation Actually Paid to PEO | |||||||||||||||||||
| 2024 | $ | $ | ( | ) | $ | $ | $ | $ | |||||||||||||||||
| (a) | The amounts deducted or added in calculating Dr. Berger’s equity award adjustments are as follows: |
| Year | Year End Fair Value of Equity Awards Granted in the Current Year | Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year | Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year | Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year | Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation | Total Equity Award Adjustments | |||||||||||||||||||||||
| 2024 | $ | $ | $ | $ | ( | ) | $ | $ | $ | |||||||||||||||||||||
| (b) | The amounts included in this column are the amounts reported in “Change in Pension and Nonqualified Deferred Compensation” column of the Summary Compensation Table for 2024. These values are $0.00 since Dr. Berger did not have any values reported in these columns in the Summary Compensation Table. | |
| (c) | The total pension benefit adjustments for 2024 include the aggregate of two components: (i) the actuarially determined service cost for services rendered by the chief executive officer during the applicable year (the “service cost”); and (ii) the entire cost of benefits granted in a plan amendment (or initiation) during the applicable year that are attributed by the benefit formula to services rendered in periods prior to the plan amendment or initiation (the “prior service cost”) calculated in accordance with U.S. GAAP. This value is $0.00 since Dr. Berger did not participate in such pension programs in Fiscal Year 2024. |
| (3) | The dollar amounts reported in column (d) and (e) represent the average of the amounts reported for the Named Executive Officers as a group (excluding Dr. Berger) in the “Total” column of the Summary Compensation Table in 2024. The names of each of the Named Executive Officers (excluding Dr. Berger) included for purposes of calculating the average amounts in each applicable year (other than 2024) are Mark Stolper, Stephen Forthuber, Norman Hames, and Mital Patel. The names of each of the Named Executive Officers (excluding Dr. Berger) included for purposes of calculating the average amounts for 2024 are Mark Stolper, Cornelis Wesdorp, Stephen Forthuber, and Norman Hames. |
| (4) | The dollar amounts reported in column (e) represent the average amount of “compensation actually paid” to the Named Executive Officers as a group (excluding Dr. Berger), as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not necessarily reflect the actual average amount of compensation earned by or paid to the Named Executive Officers as a group (excluding Dr. Berger) during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to average total compensation for the Named Executive Officers as a group (excluding Dr. Berger) for each year to determine the compensation actually paid, using the same methodology described above in Note 2: |
| Year | Average Reported Summary Compensation Table Total for Non-PEO Named Executive Officers | Average Reported Value of Equity Awards | Average Equity Award Adjustments(a) | Average Reported Change in the Actuarial Present Value of Pension Benefits(b) | Average Pension Benefit Adjustments(b) | Average Compensation Actually Paid to Non-PEO Named Executive Officers | |||||||||||||||||||
| 2024 | $ | $ | ( | ) | $ | $ | $ | $ | |||||||||||||||||
| 53 |
| (a) | The amounts deducted or added in calculating the total average equity award adjustments are as follows: |
| Year | Average Year End Fair Value of Equity Awards Granted in the Current Year | Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years | Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year | Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year | Average Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year | Average Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation | Total Average Equity Award Adjustments | ||||||||||||||||||||||
| 2024 | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||
| (b) | The amounts included in these columns are $0.00 since none of the Named Executive Officers participated in a pension benefit program in Fiscal Year 2024. |
| (5) | Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company’s share price at the end and the beginning of the measurement period by the Company’s share price at the beginning of the measurement period. |
| (6) | Represents the weighted peer group TSR, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group used for this purpose is the S&P 500 – Healthcare Sector index. |
| (7) | The dollar amounts reported represent the amount of net income reflected in the Company’s audited financial statements for the applicable year. |
| (8) |
Financial Performance Measures
As described in greater detail in the Compensation Discussion and Analysis section. the Company’s executive compensation program reflects a pay-for-performance philosophy. The metrics that the Company uses for both our long-term and short- term incentive awards are selected based on an objective of incentivizing our Named Executive Officers to increase the value of our enterprise for our shareholders. The most important financial performance measures used by the Company to link executive compensation actually paid to the Company’s Named Executive Officers, for the most recently completed fiscal year, to the Company’s performance are as follows:
1.
2.
3.
| 54 |
Analysis of the Information Presented in the Pay versus Performance Table
As described in more detail in the Compensation Discussion and Analysis section, the Company’s executive compensation program reflects a pay-for-performance philosophy. While the Company utilizes several performance measures to align executive compensation with Company performance, all of those Company measures are not presented in the Pay versus Performance table. Moreover, the Company generally seeks to incentivize long-term performance, and therefore does not specifically align the Company’s performance measures with compensation that is actually paid (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year. In accordance with Item 402(v) of Regulation S-K, the Company is providing the following descriptions of the relationships between information presented in the Pay versus Performance table.
| 55 |
Compensation Actually Paid and Net Income
Compensation Actually Paid and Adjusted EBITDA
| 56 |
EQUITY COMPENSATION PLAN INFORMATION
We have one active equity compensation plan, our Equity Incentive Plan. The Equity Incentive Plan provides for the grant of stock options (incentive and non-qualified), stock awards (including RSUs), stock appreciation rights and cash awards. If not terminated earlier, the Equity Incentive Plan will expire on April 26, 2033. As of December 31, 2024, we have reserved an aggregate 20,100,000 shares of common stock for issuance under our Equity Incentive Plan, subject to adjustment for stock dividends, reorganizations, or other changes in our capital structure and 3,172,578 shares (which excludes 358,549 shares subject to outstanding RSUs) remained available for potential future issuance. Shares underlying any portion of an award that is cancelled, terminates, expires, or lapses for any reason are generally returned to the available pool under the Equity Incentive Plan. Shares attributable to (a) shares of common stock upon the exercise of incentive stock options that are subsequently forfeited or repurchased, or (b) awards transferred under any award transfer program, shall not again be available for grant under the Equity Incentive Plan.
In connection with our acquisition of DeepHealth Inc. on June 1, 2020, we assumed the DeepHealth, Inc. 2017 Stock Incentive Plan and its then-outstanding stock options held to acquire DeepHealth, Inc. stock. After giving effect to subsequent exercises, at December 31, 2024 these assumed stock options were exercisable for up to 68,646 shares of RadNet common stock. No additional awards will be granted under the DeepHealth Inc. 2017 Stock Incentive Plan.
The following table sets forth the number of shares of common stock subject to outstanding options, RSUs, warrants and other convertible securities into share rights, the weighted-average exercise price of outstanding options, and the number of shares remaining available for future award grants as of December 31, 2024.
| Plan Category | (A) Number of Shares to Be Issued Upon Exercise of Outstanding Options, Warrants and Rights (#)(1)(2) | (B) Weighted Average Exercise Price of Outstanding Options, Warrants and Rights ($) | (C) Number of Shares Remaining Available For Future Issuance Under Equity Incentive Plans (Excluding Shares Reflected in Column (A))(3) | |||||||||
| Equity incentive plans approved by stockholders | 1,078,167 | $ | 16.43 | 3,172,578 | ||||||||
| Equity incentive plans not approved by stockholders | – | – | – | |||||||||
| TOTAL | 1,078,167 | $ | 16.43 | 3,172,578 | ||||||||
_______________
| (1) | Includes 358.549 shares subject to outstanding RSUs under the NDC Plan. The weighted average exercise price in column (B) does not take these RSUs into account. | |
| (2) | Does not include options outstanding under the DeepHealth, Inc. 2017 Stock Incentive Plan as no further awards will be made under that plan. On an aggregate basis, the number of securities to be issued upon the exercise of outstanding options originally held pursuant to the DeepHealth, Inc. 2017 Stock Incentive Plan was 68,646 on December 31, 2024, and the weighted average exercise price was $0.00. | |
| (3) | Excludes 358,549 shares subject to outstanding RSUs under the NDC Plan. |
| 57 |
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table presents information concerning the beneficial ownership of the shares of our common stock as of March 31, 2025, by:
| · | each person we know to be the beneficial owner of 5% or more of our outstanding shares of common stock; | |
| · | each of our Named Executive Officers; | |
| · | each of our directors; and | |
| · | all of our current executive officers and directors as a group. |
Unless otherwise noted below, the address of each beneficial owner listed in the table is c/o RadNet, Inc., 1510 Cotner Ave., Los Angeles, CA 90025.
Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of common stock that they beneficially own, subject to applicable community property laws.
Percentage ownership is based on 74,947,027 shares of common stock outstanding on March 31, 2025. In accordance with Securities and Exchange Commission (the “SEC”) rules, when computing the number of shares of common stock beneficially owned and the percentage ownership of a person, we include shares of common stock subject to options held by that person that are exercisable or will become exercisable within 60 days of March 31, 2025, but we do not include those shares of common stock underlying options when computing the percentage ownership of any other person.
| Name of Beneficial Owner | Shares Beneficially Owned | Percent of Shares Beneficially Owned | ||||||
| 5% or Greater Stockholders | ||||||||
| BlackRock, Inc. | 8,894,317 | (1) | 11.87% | |||||
| Sandy Nyholm Kaminsky, trustee of the HFB Heirs’ Trust II | 4,551,753 | (2) | 6.07% | |||||
| The Vanguard Group | 7,425,218 | (3) | 9.91% | |||||
| Directors, Nominees and Named Executive Officers | ||||||||
| Howard G. Berger, M.D. | 328,176 | (4) | * | |||||
| Stephen M. Forthuber | 782,479 | (5) | 1.04% | |||||
| Norman R. Hames | 380,547 | (6) | * | |||||
| Cornelis Wesdorp | 5,995 | |||||||
| Laura P. Jacobs | 24,308 | (7) | * | |||||
| Lawrence L. Levitt | 169,957 | (8) | * | |||||
| A. Gregory Sorensen, M.D. | 1,313,241 | (9) | 1.75% | |||||
| Gregory E. Spurlock | 2,591 | (10) | * | |||||
| Mark D. Stolper | 255,7585 | (11) | * | |||||
| David L. Swartz | 211,086 | (12) | * | |||||
| All directors and executive officers as a group (14 persons) | 4,255,064 | (13) | 5.60% | |||||
* Represents less than 1%.
| (1) | According to a Schedule 13G/A filed with the SEC on January 23, 2024, BlackRock, Inc. maintains sole voting power over 8,782,211 shares of our common stock and sole dispositive power over 8,894,317 shares of our common stock. The address set forth in the Schedule 13G/A filing is 50 Hudson Yards, New York, NY 10001. |
| (2) | According to a Schedule 13G/A filed with the SEC on October 24, 2024, Sandy Nyholm Kaminsky, as trustee of the HFB Heirs’ Trust II, maintains sole voting power and sole dispositive power over 4,551,753 shares of our common stock. The address set forth in the Schedule 13G filing is 400 S. Emerson Street, Denver, Colorado 80209. On June 29, 2015, HFB Enterprises, LLC, of which Dr. Berger was a co-manager, distributed 5,133,114 shares of RadNet’s common stock to HFB Heirs’ Trust II (formerly HFB Heirs’ Trust), an irrevocable trust for Dr. Berger’s children and the sole member of HFB Enterprises, LLC. Dr. Berger does not have any control over HFB Heirs’ Trust II or beneficial ownership of any of shares of RadNet common stock held by the HFB Heirs’ Trust II. |
| 58 |
| (3) | According to a Schedule 13G/A filed with the SEC on January 8, 2025, The Vanguard Group maintains shared voting power over 124,960 shares of our common stock, sole dispositive power over 7,224,863 shares of our common stock and shared dispositive power over 200,355 shares of our common stock. The address set forth in the 13G/A filing is 100 Vanguard Blvd., Malvern, PA 19355. |
| (4) | Beneficial ownership includes (a) 83,045 shares of unvested time-based restricted stock, (b) 129,961 shares subject to options exercisable within 60 days of March 31, 2025, and (c) 20,000 shares of common stock held by Dr. Berger’s spouse. |
| (5) | Beneficial ownership includes: (a) 24,466 shares of unvested time-based restricted stock, and (b) 237,194 shares subject to options exercisable within 60 days of March 31, 2025. |
| (6) | Beneficial ownership includes: (a) 18,454 shares of unvested time-based restricted stock, (b) 115,472 shares subject to options exercisable within 60 days of March 31, 2025, and (c) 27,790 shares of common stock held by Mr. Hames’s spouse. |
| (7) | Beneficial ownership includes 2,591 shares of unvested time-based restricted stock. The securities reported are held through the Jacobs Family Trust, of which Ms. Jacobs is a co-trustee. |
| (8) | Beneficial ownership includes 2,591 shares of unvested time-based restricted stock. |
| (9) | Beneficial ownership includes (a) 13,856 shares of unvested time-based restricted stock, and (b) 62,964 shares subject to options exercisable within 60 days of March 31, 2025. |
| (10) | Beneficial ownership includes 2,591 shares of unvested time-based restricted stock. |
| (11) | Beneficial ownership includes 197,998 shares subject to options exercisable within 60 days of March 31, 2025. |
| (12) | Beneficial ownership includes: (a) 2,591 shares of unvested time-based restricted stock, and (b) 37,019 shares of common stock held by Mr. Swartz’s spouse. |
| (14) | Beneficial ownership includes (a) 975,727 shares subject to options exercisable within 60 days of March 31, 2025, and (b) 405,180 shares of unvested time-based restricted stock. This beneficial ownership amount also includes 177,649 shares pledged in a margin account by Mital Patel. |
| 59 |
DELINQUENT SECTION 16(a) REPORTS
Section 16(a) of the Exchange Act requires our directors, executive officers and beneficial owners of more than 10% of our common stock to file reports of ownership and changes in ownership with the SEC. Based solely on copies of these reports provided to us and written representations that no other reports were required, we believe that these persons timely met all of the applicable Section 16(a) filing requirements during the fiscal year ended December 31, 2024, with the exception of one late report on Form 4 from David J. Katz which covered the vesting of restricted stock units subject to performance and time vesting.
| 60 |
REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS*
The Audit Committee of the Board of Directors is comprised entirely of independent directors who meet the independence requirements of NASDAQ and the SEC. The Audit Committee operates pursuant to a charter that is available on our website at www.radnet.com under Investor Relations – Corporate Governance.
The Audit Committee oversees our financial reporting process on behalf of the Board of Directors. Management is responsible for the preparation, presentation and integrity of the financial statements, including establishing accounting and financial reporting principles and designing systems of internal control over financial reporting. Our independent registered public accounting firm, Ernst & Young LLP (“Ernst & Young”), is responsible for expressing an opinion as to the conformity of our consolidated financial statements with generally accepted accounting principles.
The Audit Committee reviewed and discussed with management and Ernst & Young the audited consolidated financial statements in our annual report on Form 10-K for the year ended December 31, 2024. The Audit Committee also discussed with Ernst & Young matters required to be discussed by the Public Company Accounting Oversight Board and the SEC.
The Audit Committee has received the written disclosures and the letter from Ernst & Young required by applicable requirements of the Public Company Accounting Oversight Board regarding Ernst & Young’s communications with the Audit Committee concerning independence, and has discussed with Ernst & Young its independence.
Based on the reviews and discussions referred to above, the Audit Committee recommended to the Board of Directors that the audited consolidated financial statements discussed above be included in RadNet’s annual report on Form 10-K for the year ended December 31, 2024 for filing with the SEC. The Audit Committee has also reappointed Ernst & Young to serve as independent auditors for the fiscal year ending December 31, 2025, and requested that this appointment be submitted to our stockholders for ratification at their Annual Meeting.
Submitted by the Audit Committee:
David L. Swartz, Chair
Lawrence L. Levitt
Laura P. Jacobs
_______________
* The material in this report is not “soliciting material,” is not deemed filed with the SEC and is not to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act whether made before or after the date of this Proxy Statement and irrespective of any general incorporation language therein.
| 61 |
PROPOSALS
PROPOSAL NO. 1:
ELECTION OF DIRECTORS
Based on the recommendation of our Nominating and Governance Committee, our Board of Directors has nominated each of the following individuals to be elected to serve on our Board until the next annual meeting of stockholders and until their successors are duly elected and qualified:
Howard G. Berger, M.D.,
Laura P. Jacobs,
Lawrence L. Levitt,
A. Gregory Sorensen, M.D.
Gregory E. Spurlock, and
David L. Swartz
Each of the nominees is a current director and all have consented to serving as a nominee, being named in this Proxy Statement, and serving on the Board if elected. Each director elected at the Annual Meeting will be elected to serve a one-year term. If any nominee becomes unavailable or unable to serve before the Annual Meeting, the Board of Directors may determine to leave the position vacant, reduce the number of authorized directors or designate a substitute nominee. If a substitute nominee is named, then the persons named as proxies will have full discretion and authority to vote or refrain from voting for such substitute nominee in their discretion.
There are no family relationships between any nominees and executive officers of RadNet, and there are no arrangements or understandings between any nominee and any other person pursuant to which such nominee was or is selected as a director or nominee.
Vote Required
In accordance with our bylaws, the election of a director in an uncontested election requires the affirmative vote of the holders of a majority of the shares present in person or represented by proxy and entitled to vote on this proposal at the Annual Meeting.
Board of Director Recommendation
OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” EACH OF THE NOMINEES ABOVE.
| 62 |
PROPOSAL NO. 2:
RATIFICATION OF THE APPOINTMENT OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Our Audit Committee has re-appointed Ernst & Young LLP (“Ernst & Young”) as our independent registered public accounting firm for the fiscal year ending December 31, 2025. Ernst & Young has audited our financial statements annually since January 1, 2007. Our Audit Committee reviews the appointment of our independent accounting firm annually.
At the Annual Meeting, our stockholders are being asked to ratify the appointment of Ernst & Young as our independent registered public accounting firm for 2025. If our stockholders vote against the ratification of Ernst & Young, the Audit Committee will consider this in its selection of auditors for the following year. Even if our stockholders ratify the appointment, the Audit Committee may choose to appoint a different independent registered public accounting firm at any time during the year if it is determined that such a change would be in the best interests of RadNet and its stockholders. Representatives of Ernst & Young are expected to be at the Annual Meeting to answer any questions and make a statement should they choose to do so.
Fees Paid to Auditors
The following table presents fees billed by Ernst & Young for the fiscal years ended December 31, 2023 and 2024.
| 2023 | 2024 | |||||||
| Audit Fees(1) | $ | 3,267,120 | $ | 3,479,220 | ||||
| Audit-Related Fees(2) | – | 670,000 | ||||||
| Tax Fees(3) | ||||||||
| Tax Compliance Fees | 764,670 | 872,870 | ||||||
| Other Tax Fees | 270,231 | 426,746 | ||||||
| All Other Fees(4) | 3,600 | 3,600 | ||||||
| Total | $ | 4,305,621 | $ | 5,452,436 | ||||
_______________
| (1) | Audit Fees in fiscal years ended December 31, 2023 and 2024 consisted of fees billed for professional services rendered in connection with the audit of our annual financial statements and internal control over financial reporting, quarterly review of interim consolidated financial statements and audit services in connection with other statutory and regulatory filings. | |
| (2) | Ernst & Young did not render any Audit-Related Fees in the fiscal year ended December 31, 2023. | |
| (3) | Tax fees in the fiscal years ended December 31, 2023 and 2024 consisted of fees billed for professional services rendered for tax compliance, tax advice and tax planning. These services included assistance regarding federal and state tax compliance, acquisitions and tax planning. | |
| (4) | All Other Fees in the fiscal years ended December 31, 2023 and 2024 consisted of fees for products and services other than the services reported above. |
Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of the Independent Registered Public Accounting Firm
As a matter of policy, all audit and non-audit services provided by our independent registered public accounting firm are approved in advance by the Audit Committee, which considers whether the provision of non-audit services is compatible with maintaining such firm’s independence. All services provided by Ernst & Young during the fiscal year ended December 31, 2024 and the fiscal year ended December 31, 2023 were pre-approved by the Audit Committee. The Audit Committee has considered the role of Ernst & Young in providing services to us for the fiscal year ending December 31, 2025 and has concluded that such services are compatible with their independence as our auditors.
Vote Required
Ratification of Ernst & Young as our independent registered public accounting firm requires the affirmative vote of the holders of a majority of the shares present in person or represented by proxy on this proposal at the Annual Meeting.
Board of Director Recommendation
OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” PROPOSAL 2.
| 63 |
PROPOSAL NO. 3:
ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS
In accordance with the requirements of Section 14A of the Exchange Act and the related rules of the SEC, our stockholders have the opportunity to cast an annual advisory vote to approve the compensation of our Named Executive Officers as disclosed in this Proxy Statement, including the Compensation Discussion and Analysis, the summary compensation and other related tables and narratives accompanying those tables (a “say-on-pay” vote).
We currently hold our advisory say-on-pay vote every year. Stockholders will have an opportunity to cast an advisory vote on the frequency of say-on-pay votes at least every six years. We currently expect that the next advisory vote on the frequency of the say-on-pay votes will occur at the 2029 annual meeting of stockholders.
We intend that our compensation program and decisions will attract and retain our Named Executive Officers and reward them for achieving RadNet’s strategic initiatives and objective measures of success. We compensate our executive officers through a mix of base salary, bonus and equity compensation. Our Compensation Committee and Board of Directors believe that our executive compensation program is effective in implementing our principles and is strongly aligned with the long-term interests of our stockholders and that our stockholders should approve our compensation program.
Approximately 89% of votes cast (excluding abstentions and broker non-votes) on the say on pay advisory proposal at our 2024 Annual Meeting were voted in favor of our executive compensation program.
The vote on this resolution is not intended to address any specific element of compensation; rather, the vote relates to the overall compensation of our Named Executive Officers. We encourage our stockholders to read the “Compensation Discussion and Analysis” section above, which describes the details of our executive compensation program and the decisions made by the Compensation Committee for 2024.
Accordingly, our stockholders are being asked to vote on the following resolution at the Annual Meeting:
“RESOLVED, that the compensation paid to RadNet’s Named Executive Officers, as disclosed in this Proxy Statement pursuant to the SEC’s executive compensation disclosure rules, including Compensation Discussion and Analysis, compensation tables and narrative discussion, is hereby APPROVED.”
The vote is advisory and its outcome will not be binding on our Board of Directors nor require our Board of Directors or Compensation Committee to take any action. However, our Board of Directors and Compensation Committee value the opinion expressed by our stockholders in their vote on this proposal and expect to take into account the outcome of this vote when evaluating future executive compensation arrangements for our Named Executive Officers.
Vote Required
Approval of the compensation of our Named Executive Officers for the stockholder advisory vote requires the affirmative vote of the holders of a majority of the shares present in person or represented by proxy and entitled to vote on this proposal at the Annual Meeting.
Board of Director Recommendation
OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” PROPOSAL 3.
| 64 |
OTHER MATTERS
We know of no other matters to be submitted at the Annual Meeting. If any other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the Proxy Card for the Annual Meeting to exercise their discretionary authority to vote the shares that they represent in accordance with their judgment.
ADDITIONAL INFORMATION
Further Information
For further information about RadNet, please refer to the 2024 Annual Report. The 2024 Annual Report is publicly available on the SEC’s website at www.sec.gov and on our website at www.radnet.com. You may also obtain a copy by sending a written request to Investor Relations, RadNet, Inc., 1510 Cotner Ave., Los Angeles, CA 90025.
Householding
Some banks, brokers and other nominee record holders may be participating in the practice of “householding” proxy statements and annual reports. This means that only one Notice of Availability or, if you have requested paper copies, only one set of proxy materials is delivered to multiple stockholders sharing an address. If you are a stockholder sharing an address, you can request a separate Notice of Availability or copy of the proxy materials by contacting the Broadridge Householding Department by phone at 1-866-540-7095 or by mail to Broadridge Householding Department, 51 Mercedes Way, Edgewood, NY 11717. A separate copy will be promptly provided following receipt of your request, and you will receive separate materials in the future. If you currently share an address with another stockholder but are nonetheless receiving separate copies of the materials, you may request delivery of a single copy in the future by contacting the Broadridge Householding Department at the number or address shown above.
Director Nominations and Stockholder Proposals for Inclusion in RadNet, Inc.’s 2025 Proxy Materials
Our bylaws provide that, for stockholder nominations to the Board of Directors or other proposals to be considered at an annual meeting, the stockholder must have given timely advance notice of the proposal or nomination in writing to our Corporate Secretary.
To be timely for the 2026 Annual Meeting of Stockholders, a stockholder’s notice must be delivered to or mailed and received by our Corporate Secretary at our principal executive offices between February 10, 2026 and March 12, 2026. A stockholder’s notice to the Corporate Secretary must set forth the information required by our bylaws as to each matter the stockholder proposes to bring before the 2026 Annual Meeting of Stockholders.
Stockholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), must be received by us not later than December 26, 2025, in order to be considered for inclusion in our proxy materials for the 2026 Annual Meeting of Stockholders.
The deadline for providing notice to the Company under Rule 14a-19, the SEC’s universal proxy rule, of a shareholder’s intent to solicit proxies in support of nominees submitted under the Company’s advance notice bylaws for our 2026 Annual Meeting of Stockholders is March 12, 2026. Shareholders intending to provide such a notice must comply with all requirements of Rule 14a-19 in addition to all requirements under our bylaws, including the timing of notice requirements described above.
By Order of the Board of Directors,
David Katz
Corporate Secretary
| 65 |
